The University of Chicago Header Logo

Richard A. Larson

TitleProfessor
InstitutionUniversity of Chicago
DepartmentMedicine-Hematology and Oncology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of Chicago, Chicago, ILFellowship1983Hematology & Oncology
    University of Chicago, Chicago. ILResidency1980Internal Medicine
    Stanford University School of Medicine, Stanford, CAMD1977Medicine
    King's College, University of Cambridge, Cambridge, England1973Chemistry
    Dartmouth College, Hanover, NHAB1972Chemistry

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Madero-Marroquin R, Dworkin E, Weiner H, Saygin C, Nawas MT, Drazer MW, DuVall AS, Kosuri S, Thirman MJ, Odenike O, Stock W, Larson RA, Patel AA. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 Mar 05; 1-4. PMID: 38441062.
      Citations:    Fields:    
    2. Appelbaum JS, Wei AH, Mandrekar SJ, Tiong IS, Chua CC, Teh TC, Fong CY, Ting SB, Weber D, Benner A, Hill H, Saadati M, Yin J, Stone RM, Garcia-Manero G, Erba HP, Uy GL, Marcucci G, Larson RA, Thomas A, Freeman SD, Almuina NM, Döhner K, Thomas I, Russel NH, Döhner H, Othus M, Estey EH, Walter RB. Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts. Leukemia. 2024 02; 38(2):389-392. PMID: 38263433; PMCID: PMC10996038.
      Citations:    Fields:    
    3. Woyach JA, Perez Burbano GE, Ruppert AS, Miller CR, Heerema NA, Zhao W, Wall A, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Stephens DM, Brown JR, Lozanski G, Blachly JS, Nattam S, Larson RA, Erba HP, Litzow MR, Luger SM, Owen C, Kuzma C, Abramson JS, Little RF, Dinner SN, Stone RM, Uy GL, Stock W, Mandrekar SJ, Byrd JC. Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL. Blood. 2024 Jan 12. PMID: 38215395.
      Citations:    Fields:    
    4. Johnston H, Youshanlouei HR, Osei C, Patel AA, DuVall A, Wang P, Wanjari P, Segal J, Venkataraman G, Cheng JX, Gurbuxani S, Lager A, Fitzpatrick C, Thirman M, Nawas M, Liu H, Drazer M, Odenike O, Larson R, Stock W, Saygin C. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171. PMID: 38039510; PMCID: PMC10787242.
      Citations:    Fields:    Translation:Humans
    5. Saygin C, Zhang P, Stauber J, Aldoss I, Sperling AS, Weeks LD, Luskin MR, Knepper TC, Wanjari P, Wang P, Lager AM, Fitzpatrick C, Segal JP, Gharghabi M, Gurbuxani S, Venkataraman G, Cheng JX, Eisfelder BJ, Bohorquez O, Patel AA, Umesh Nagalakshmi S, Jayaram S, Odenike OM, Larson RA, Godley LA, Arber DA, Gibson CJ, Munshi NC, Marcucci G, Ebert BL, Greally JM, Steidl U, Lapalombella R, Shah BD, Stock W. Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis. Blood Cancer Discov. 2023 Dec 27. PMID: 38150184.
      Citations:    Fields:    
    6. Madero-Marroquin R, DuVall AS, Saygin C, Wang P, Gurbuxani S, Larson RA, Stock W, Patel AA. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 Apr; 204(4):1238-1242. PMID: 38073116.
      Citations:    Fields:    
    7. Winn AN, Atallah E, Cortes J, Deininger MWN, Kota V, Larson RA, Moore JO, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Shah NP, Thompson JE, Flynn KE. Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia. JAMA Netw Open. 2023 Dec 01; 6(12):e2347950. PMID: 38109114; PMCID: PMC10728762.
      Citations:    Fields:    Translation:Humans
    8. Ozga M, Nicolet D, Mrózek K, Yilmaz AS, Kohlschmidt J, Larkin KT, Blachly JS, Oakes CC, Buss J, Walker CJ, Orwick S, Jurinovic V, Rothenberg-Thurley M, Dufour A, Schneider S, Sauerland MC, Görlich D, Krug U, Berdel WE, Woermann BJ, Hiddemann W, Braess J, Subklewe M, Spiekermann K, Carroll AJ, Blum WG, Powell BL, Kolitz JE, Moore JO, Mayer RJ, Larson RA, Uy GL, Stock W, Metzeler KH, Grimes HL, Byrd JC, Salomonis N, Herold T, Mims AS, Eisfeld AK. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). Leukemia. 2024 01; 38(1):45-57. PMID: 38017103; PMCID: PMC10776397.
      Citations:    Fields:    Translation:Humans
    9. Garcia-Manero G, Podoltsev NA, Othus M, Pagel JM, Radich JP, Fang M, Rizzieri DA, Marcucci G, Strickland SA, Litzow MR, Savoie ML, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Kolitz JE, Larson RA, Stone RM, Claxton D, Essell J, Luger SM, Mohan SR, Moseley A, Appelbaum FR, Erba HP. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia. 2024 01; 38(1):58-66. PMID: 37935977.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    10. Balema W, Morton J, Larson RA, Li L, Velasquez FC, Fowlkes NW, Krishnamurthy S, Debeb BG, Sevick-Muraca E, Woodward WA. High-fat diet, but not duration of lactation, increases mammary gland lymphatic vessel function and subsequent growth of inflammatory breast cancer cells. J Mammary Gland Biol Neoplasia. 2023 10 06; 28(1):21. PMID: 37801190; PMCID: PMC10558390.
      Citations: 1     Fields:    Translation:HumansAnimals
    11. Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, Mannis G, Chai-Ho W, Tanaka TN, Bradley TJ, Jeyakumar D, Wang ES, Sweet K, Kantarjian HM, Garcia-Manero G, Komrokji R, Xing G, Ramsingh G, Renard C, Zeidner JF, Sallman DA. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. J Clin Oncol. 2023 11 01; 41(31):4893-4904. PMID: 37703506; PMCID: PMC10617926.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    12. Rebechi M, Kohlschmidt J, Mrózek K, Nicolet D, Mims AS, Blachly JS, Orwick S, Larkin KT, Oakes CC, Hantel A, Carroll AJ, Blum WG, Powell BL, Uy GL, Stone RM, Larson RA, Byrd JC, Paskett ED, Plascak JJ, Eisfeld AK. Association of social deprivation with survival in younger adult patients with AML: an Alliance study. Blood Adv. 2023 08 08; 7(15):4019-4023. PMID: 37196637; PMCID: PMC10425796.
      Citations: 1     Fields:    Translation:Humans
    13. Roloff GW, Wen F, Ramsland A, Artz AS, Kosuri S, Stock W, Odenike O, Larson RA, Liu H, Godley LA, Thirman MJ, Patel AA, Daugherty CK, DuVall AS, Nawas MT, Dworkin E, Wool GD, Gurbuxani S, Fitzpatrick C, Segal JP, Wang P, Drazer MW. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239. PMID: 36655425; PMCID: PMC10388285.
      Citations:    Fields:    Translation:Humans
    14. DuVall AS, Wesevich A, Larson RA. Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma. Curr Hematol Malig Rep. 2023 Dec; 18(6):217-225. PMID: 37490229.
      Citations:    Fields:    Translation:HumansCells
    15. Radich JP, Wall M, Branford S, Campbell CD, Chaturvedi S, DeAngelo DJ, Deininger M, Guinney J, Hughes TP, Kantarjian HM, Larson RA, Li S, Maegawa R, Mishra K, Obourn V, Pinilla-Ibarz J, Purkayastha D, Sadek I, Saglio G, Shrestha A, White BS, Druker BJ, Hochhaus A. Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis. Haematologica. 2023 06 01; 108(6):1567-1578. PMID: 36727397; PMCID: PMC10230428.
      Citations: 1     Fields:    Translation:Humans
    16. Tran MC, Hasan Y, Wang A, Yenice K, Partouche J, Stock W, Larson RA, Kosuri S, LaBelle JL, Kline J, Riedell PA, Artz AS, Weichselbaum R, Bishop MR, Aydogan B, Liu H. A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Adv. 2023 02 14; 7(3):285-292. PMID: 35851593; PMCID: PMC9898602.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    17. Aldoss I, Yin J, Wall A, Liedtke M, Claxton DF, Foster MC, Appelbaum FR, Erba HP, Litzow MR, Tallman MS, Stone RM, Larson RA, Advani AS, Stock W, Luger SM, Mrózek K. The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study. Blood Adv. 2023 01 24; 7(2):196-204. PMID: 36269846; PMCID: PMC9841239.
      Citations: 1     Fields:    Translation:Humans
    18. Montesinos P, Schuh AC, Vyas P, Wei AH, Semochkin S, Kim HJ, Larson RA, Koprivnikar J, Frankfurt O, Thol F, Byrne J, Pigneux A, Thomas X, Salamero O, Doronin V, Fathi AT, Laille E, Yu X, Hasan M, Martin-Regueira P, DiNardo CD, de Botton S, Papayannidis C, Ommen H, Chromik J, Vidriales MB, Döhner H. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. Blood. 2023 01 12; 141(2):156-167. PMID: 35714312; PMCID: PMC10644040.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    19. Bombaci F, Ramscar N, Hughes TP, Cortes JE, Hochhaus A, Takahashi N, Larson RA, Issa GC, Ifrah S. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncol. 2022 Dec; 18(38):4161-4170. PMID: 36524980.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    20. Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Sierra J, Montesinos P, Yoon SS, Maeda Y, Hosono N, Onozawa M, Kato T, Kim HJ, Levis MJ, Hasabou N, Nuthethi R, Tiu R, Neubauer A, Recher C. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. Transplant Cell Ther. 2023 04; 29(4):265.e1-265.e10. PMID: 36526260; PMCID: PMC10189888.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    21. Shih AJ, Jun T, Skol AD, Bao R, Huang L, Vora S, McNerney ME, Hungate EA, Le Beau MM, Larson RA, Elliott A, Lu HM, Huether R, Hernandez F, Allan JM, Onel K, Stölzel F. Inherited cancer predisposing mutations in patients with therapy-related myeloid neoplasms. Br J Haematol. 2023 02; 200(4):489-493. PMID: 36349721.
      Citations: 1     Fields:    Translation:Humans
    22. Flynn KE, Atallah E, Lin L, Shah NP, Silver RT, Larson RA, Panilla-Ibarz J, Thompson JE, Oehler VG, Radich JP, Kota V, Mauro MJ, Schiffer CA, Cortes J, Weinfurt KP. Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. Haematologica. 2022 11 01; 107(11):2641-2649. PMID: 35511672; PMCID: PMC9614525.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    23. Larkin KT, Nicolet D, Kelly BJ, LaHaye S, Miller KE, Wijeratne S, Wheeler G, Kohlschmidt J, Blachly JS, Mims AS, Walker CJ, Oakes CC, Orwick S, Boateng I, Buss J, Heyrosa A, Desai H, Carroll AJ, Blum W, Powell BL, Kolitz JE, Moore JO, Mayer RJ, Larson RA, Stone RM, Paskett ED, Byrd JC, Mardis ER, Eisfeld AK, Mrózek K. High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML. Blood Adv. 2022 10 11; 6(19):5570-5581. PMID: 35788257; PMCID: PMC9577622.
      Citations: 3     Fields:    Translation:Humans
    24. Weber D, Krzykalla J, Fiedler W, Salwender H, Fransecky L, Mayer K, Hertenstein B, Tischler HJ, Machherndl-Spandl S, Schrade A, Paschka P, Gaidzik VI, Theis F, Thol F, Heuser M, Schlenk RF, Saadati M, Benner A, Larson R, Stone R, Ganser A, Döhner H, Wulf G, Salih H, Lübbert M, Kühn MWM, Schroeder T, Götze K, Westermann J, Ringhoffer M, Bullinger L, Döhner K. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. Blood Adv. 2022 09 27; 6(18):5345-5355. PMID: 35486475; PMCID: PMC9631686.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    25. Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Ebert BL, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Döhner H, Dombret H, Fenaux P, Röllig C, Löwenberg B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 09 22; 140(12):1345-1377. PMID: 35797463.
      Citations: 413     Fields:    Translation:Humans
    26. Yu B, Osman AEG, Sladojevic N, Prabhu N, Tai HC, Chen D, Perla G, Park L, Larson RA, Liao JK. Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity. JACC CardioOncol. 2022 Sep; 4(3):371-383. PMID: 36213346; PMCID: PMC9537085.
      Citations: 1     
    27. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes JE, Dal Cin P, DiNardo CD, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Godley LA, Gotlib J, Hobbs GS, Hoffman R, Jabbour EJ, Larson RA, Le Beau MM, Loh ML, Malcovati L, Mullighan CG, Niemeyer C, Odenike OM, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer CA, Schmitt-Graeff A, Shimamura A, Sierra J, Stock WA, Stone RM, Tallman MS, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Tefferi A, Kvasnicka HM, Dombret H, Gianelli U, Gökbuget N, Hellström-Lindberg E, Kiladjian JJ, Löwenberg B, Macintyre E, Thiele J, Döhner H. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 09 15; 140(11):1200-1228. PMID: 35767897; PMCID: PMC9479031.
      Citations: 359     Fields:    Translation:Humans
    28. Jahn N, Jahn E, Saadati M, Larson RA, Ottone T, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Heuser M, Ganser A, Pallaud C, Gathmann I, Krzykalla J, Benner A, Bloomfield CD, Stone RM, Bullinger L, Ehninger G, Thiede C, Döhner H, Döhner K. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial. Leukemia. 2022 09; 36(9):2218-2227. PMID: 35922444; PMCID: PMC9417991.
      Citations: 5     Fields:    Translation:Humans
    29. Muffly L, Yin J, Jacobson S, Wall A, Quiroz E, Advani AS, Luger SM, Tallman MS, Litzow MR, Foster MC, Erba HP, Appelbaum FR, Larson RA, Keegan THM, Stock W. Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. Blood Adv. 2022 07 26; 6(14):4085-4092. PMID: 35838753; PMCID: PMC9327550.
      Citations: 3     Fields:    Translation:Humans
    30. Ritchie EK, Klepin HD, Storrick E, Major B, Le-Rademacher J, Wadleigh M, Walker A, Larson RA, Roboz GJ. Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101. Blood Adv. 2022 06 28; 6(12):3812-3820. PMID: 35420672; PMCID: PMC9631575.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    31. Epstein-Peterson ZD, Derkach A, Geyer S, Kohlschmidt J, Park JH, Rajeeve S, Stein EM, Zhang Y, Iland H, Campbell LJ, Larson RA, Powell BL, Stock W, Stone RM, Tallman MS, Mrózek K, Poiré X. Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. Blood Adv. 2022 06 14; 6(11):3433-3439. PMID: 35349669; PMCID: PMC9198910.
      Citations: 3     Fields:    Translation:Humans
    32. Hantel A, Kohlschmidt J, Eisfeld AK, Stock W, Jacobson S, Mandrekar S, Larson RA, Stone RM, Lathan CS, DeAngelo DJ, Byrd JC, Abel GA. Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. J Clin Oncol. 2022 11 10; 40(32):3709-3718. PMID: 35696629; PMCID: PMC9649272.
      Citations: 4     Fields:    Translation:Humans
    33. Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Sierra J, Montesinos P, Yoon SS, Hosono N, Onozawa M, Chiba S, Kim HJ, Hasabou N, Lu Q, Tiu R, Levis MJ, Neubauer A, Récher C. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022 06 09; 139(23):3366-3375. PMID: 35081255; PMCID: PMC9197557.
      Citations: 25     Fields:    Translation:Humans
    34. Gambacorti-Passerini C, Larson RA, Aroldi A, Fontana D, Piazza R, Antolini L, Assouline S, Nicolini FE, le Coutre P. Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia. Am J Hematol. 2022 08; 97(8):E296-E298. PMID: 35604243; PMCID: PMC9543833.
      Citations: 1     Fields:    Translation:Humans
    35. Laurie KL, Lee P, Rademaker A, Alonzo TA, Wang YC, Powell BL, Wu D, Larson R, Kutny M, Gregory J, Hijiya N, Feusner J. Obesity in children with acute promyelocytic leukemia: What is its prevalence and prognostic significance? Pediatr Blood Cancer. 2022 06; 69(6):e29613. PMID: 35322524; PMCID: PMC9553282.
      Citations: 1     Fields:    Translation:Humans
    36. Schoenbeck KL, Atallah E, Lin L, Weinfurt KP, Cortes J, Deininger MWN, Kota V, Larson RA, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Schiffer CA, Shah NP, Silver RT, Thompson JE, Flynn KE. Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. J Natl Cancer Inst. 2022 01 11; 114(1):160-164. PMID: 34491344; PMCID: PMC8755495.
      Citations: 6     Fields:    Translation:Humans
    37. Lin WY, Fordham SE, Hungate E, Sunter NJ, Elstob C, Xu Y, Park C, Skol A, Rahman T, Sucheston-Campbell L, Wang J, Hahn T, Clay-Gilmour AI, Jones GL, Marr HJ, Jackson GH, Menne T, Collin M, Ivey A, Hills RK, Burnett AK, Russell NH, Fitzgibbon J, Larson RA, Le Beau MM, Stock W, Heidenreich O, Alharbi A, Allsup DJ, Houlston RS, Norden J, Dickinson AM, Douglas E, Lendrem C, Daly AK, Palm L, Piechocki K, Jeffries S, Altmann H, Ruhnke L, Kunadt D, Cordell HJ, Darlay R, Andersen MK, Martinelli G, Marconi G, Cluzeau T, Raynaud S, Sill H, Cheok M, Preudhomme C, Gale RE, Linch D, Gaal-Wesinger J, Masszi A, Nowak D, Hofmann WK, Gilkes A, Porkka K, Milosevic Feenstra JD, Kralovics R, Grimwade D, Meggendorfer M, Haferlach T, Onel K, Allan JM, Quante A, Strauch K, Gieger C, Bornhäuser M, Röllig C, Wagenführ L, Fontana MC, Sanz MA, Cervera J, Gómez-Seguí I, Moreilhon C, Voso MT, Lo-Coco F, Dombret H, Krizsán S, Bödör C, Stölzel F. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nat Commun. 2022 Jan 04; 13(1):2. PMID: 34983928; PMCID: PMC8727612.
      Citations: 1     Fields:    
    38. Wieduwilt MJ, Yin J, Wetzler M, Uy GL, Powell BL, Kolitz JE, Liedtke M, Stock W, Beumer JH, Mattison RJ, Storrick E, Christner SM, Lewis LD, Devine S, Stone RM, Larson RA. Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. Blood Adv. 2021 11 23; 5(22):4691-4700. PMID: 34492682; PMCID: PMC8759134.
      Citations: 3     Fields:    Translation:HumansCells
    39. Lin WY, Fordham SE, Hungate E, Sunter NJ, Elstob C, Xu Y, Park C, Skol A, Rahman T, Sucheston-Campbell L, Wang J, Hahn T, Clay-Gilmour AI, Jones GL, Marr HJ, Jackson GH, Menne T, Collin M, Ivey A, Hills RK, Burnett AK, Russell NH, Fitzgibbon J, Larson RA, Le Beau MM, Stock W, Heidenreich O, Alharbi A, Allsup DJ, Houlston RS, Norden J, Dickinson AM, Douglas E, Lendrem C, Daly AK, Palm L, Piechocki K, Jeffries S, Altmann H, Ruhnke L, Kunadt D, Cordell HJ, Darlay R, Andersen MK, Martinelli G, Marconi G, Cluzeau T, Raynaud S, Sill H, Cheok M, Preudhomme C, Gale RE, Linch D, Gaal-Wesinger J, Masszi A, Nowak D, Hofmann WK, Gilkes A, Porkka K, Milosevic Feenstra JD, Kralovics R, Grimwade D, Meggendorfer M, Haferlach T, Onel K, Allan JM, Quante A, Strauch K, Gieger C, Bornhäuser M, Röllig C, Wagenführ L, Fontana MC, Sanz MA, Cervera J, Gómez-Seguí I, Moreilhon C, Voso MT, Lo-Coco F, Dombret H, Krizsán S, Bödör C, Stölzel F. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nat Commun. 2021 10 29; 12(1):6233. PMID: 34716350; PMCID: PMC8556284.
      Citations: 10     Fields:    Translation:Humans
    40. Luger SM, Wang VX, Rowe JM, Litzow MR, Paietta E, Ketterling RP, Lazarus H, Rybka WB, Craig MD, Karp J, Cooper BW, Makary AZ, Kaminer LS, Appelbaum FR, Larson RA, Tallman MS. Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. Leuk Res. 2021 12; 111:106736. PMID: 34773794; PMCID: PMC8643322.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    41. Patel AA, Rojek AE, Drazer MW, Weiner H, Godley LA, Le Beau MM, Larson RA. Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy. Blood Adv. 2021 10 26; 5(20):4140-4148. PMID: 34492705; PMCID: PMC8945635.
      Citations: 6     Fields:    Translation:HumansCells
    42. Clarke WA, Fotoohi AK, Larson RA, Martin JH, Mathijssen RHJ, Salamone SJ, Chatelut E. Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. Eur J Cancer. 2021 11; 157:428-440. PMID: 34597977.
      Citations: 12     Fields:    Translation:Humans
    43. Du L, Benner A, Krzykalla J, Gathmann I, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Savoie L, Sierra J, Pallaud C, Sanz MA, Jansen JH, Niederwieser D, Fischer T, Heuser M, Ganser A, Larson RA, Bloomfield CD, Stone RM, Rücker FG, Luck TJ, Voso MT, Amadori S, Ehninger G, Bullinger L, Döhner H, Thiede C, Döhner K. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia. 2022 01; 36(1):90-99. PMID: 34316017; PMCID: PMC8727286.
      Citations: 26     Fields:    Translation:HumansCells
    44. Ruppert AS, Booth AM, Ding W, Bartlett NL, Brander DM, Coutre S, Brown JR, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma CS, Abramson JS, Little RF, Smith SE, Stone RM, Byrd JC, Mandrekar SJ, Woyach JA. Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia. 2021 10; 35(10):2854-2861. PMID: 34274940; PMCID: PMC8744070.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    45. Walker AR, Marcucci G, Yin J, Blum W, Stock W, Kohlschmidt J, Carroll AJ, Eisfeld AK, Wang ES, Jacobson S, Kolitz JE, Thakuri M, Sutamtewagul G, Vij R, Stuart RK, Byrd JC, Bloomfield CD, Stone RM, Larson RA, Mrózek K. Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Adv. 2021 07 13; 5(13):2775-2787. PMID: 34251414; PMCID: PMC8288671.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    46. Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf D. Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia. 2021 Jul; 35(7):2140. PMID: 34088982; PMCID: PMC8329698.
      Citations: 1     Fields:    
    47. Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, Boquimpani C, Clark RE, Dubruille V, Flinn IW, Kyrcz-Krzemien S, Medras E, Cacciatore S, Titorenko K, Aimone P, Saglio G, le Coutre P, Etienne G, Pasquini R, Zanichelli M, Bendit I, Hochhaus A. Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021 Jul; 35(7):2142-2143. PMID: 34108614; PMCID: PMC8414785.
      Citations: 2     Fields:    
    48. Patel AA, Heng J, Dworkin E, Monick S, Derman BA, DuVall AS, Gurbuxani S, Kosuri S, Liu H, Thirman M, Godley LA, Odenike O, Larson RA, Stock W. Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. EJHaem. 2021 Aug; 2(3):413-420. PMID: 35844676; PMCID: PMC9175801.
      Citations: 2     
    49. Schmalbrock LK, Cocciardi S, Theis F, Jahn N, Panina E, Herzig J, Skambraks S, Gaidzik VI, Paschka P, Fiedler W, Schlenk RF, Thol F, Heuser M, Larson RA, Ganser A, Stunnenberg HG, Minucci S, Stone RM, Bloomfield CD, Dolnik A, Sträng E, Blätte TJ, Rücker FG, Salih HR, Wulf G, Schroeder T, Lübbert M, Döhner H, Döhner K, Bullinger L. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021 06 03; 137(22):3093-3104. PMID: 33598693; PMCID: PMC8233666.
      Citations: 54     Fields:    Translation:HumansCellsCTClinical Trials
    50. Jiang Q, Larson RA, Gale RP. Economics influences therapy decisions in chronic myeloid leukaemia: should it? J Cancer Res Clin Oncol. 2021 Dec; 147(12):3693-3698. PMID: 33885952.
      Citations: 2     Fields:    Translation:Humans
    51. Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf D. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia. 2021 07; 35(7):2076-2085. PMID: 33785862; PMCID: PMC8257494.
      Citations: 12     Fields:    Translation:Humans
    52. Larson RA, Mandrekar SJ, Huebner LJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Prior TW, Marcucci G, Voso MT, Klisovic RB, Galinsky I, Wei AH, Sierra J, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Serve H, Amadori S, Gathmann I, Stone RM, Thiede C, Döhner K, Sanz MA, Krauter J, Ehninger G, Döhner H. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia. 2021 09; 35(9):2539-2551. PMID: 33654204; PMCID: PMC8591906.
      Citations: 32     Fields:    Translation:Humans
    53. Lu P, Wang S, Franzen CA, Venkataraman G, McClure R, Li L, Wu W, Niu N, Sukhanova M, Pei J, Baldwin DA, Nejati R, Wasik MA, Khan N, Tu Y, Gao J, Chen Y, Ma S, Larson RA, Wang YL. Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer J. 2021 02 18; 11(2):39. PMID: 33602908; PMCID: PMC7893066.
      Citations: 14     Fields:    Translation:HumansCells
    54. Wei AH, Ribera JM, Larson RA, Ritchie D, Ghobadi A, Chen Y, Anderson A, Dos Santos CE, Franklin J, Kantarjian H. Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia. 2021 08; 35(8):2220-2231. PMID: 33542479; PMCID: PMC8324476.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    55. Advani AS, Larsen E, Laumann K, Luger SM, Liedtke M, Devidas M, Chen Z, Yin J, Foster MC, Claxton D, Coffan K, Tallman MS, Appelbaum FR, Erba H, Stone RM, Hunger SP, McNeer JL, Loh ML, Raetz E, Winick N, Carroll W, Larson RA, Stock W. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021 01 26; 5(2):504-512. PMID: 33496745; PMCID: PMC7839367.
      Citations: 14     Fields:    Translation:Humans
    56. Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, Boquimpani C, Clark RE, Dubruille V, Flinn IW, Kyrcz-Krzemien S, Medras E, Cacciatore S, Titorenko K, Aimone P, Saglio G, le Coutre P, Etienne G, Pasquini R, Zanichelli M, Bendit I, Hochhaus A. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021 02; 35(2):440-453. PMID: 33414482; PMCID: PMC7862065.
      Citations: 73     Fields:    Translation:Humans
    57. Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. JAMA Oncol. 2021 Jan 01; 7(1):42-50. PMID: 33180106; PMCID: PMC7662490.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    58. Voso MT, Larson RA, Jones D, Marcucci G, Prior T, Heuser M, Lavorgna S, Geyer SM, Walker A, Wei AH, Sanz MA, Brandwein JM, de Witte TM, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Amadori S, Cheng Y, Chen Y, Pallaud C, Du L, Piciocchi A, Byrd J, Stone RM, Bloomfield CD, Lo-Coco F, Krauter J, Nomdedeu J, Sierra J, Ehninger G, Thiede C, Döhner K, Döhner H. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Adv. 2020 10 13; 4(19):4945-4954. PMID: 33049054; PMCID: PMC7556122.
      Citations: 20     Fields:    Translation:Humans
    59. Cooperrider JH, Fulton N, Artz AS, Larson RA, Stock W, Kosuri S, Bishop M, Liu H. Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2020 11; 55(11):2204-2206. PMID: 32376970.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    60. Patel AA, Cahill K, Charnot-Katsikas A, Liu H, Gurbuxani S, Thirman M, Kosuri S, Artz AS, Larson RA, Stock W, Segal J, Odenike O. Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51. PMID: 32358888.
      Citations: 13     Fields:    Translation:Humans
    61. Klepin HD, Neuendorff NR, Larson RA, Hamaker ME, Breccia M, Montesinos P, Cordoba R. Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force. J Geriatr Oncol. 2020 11; 11(8):1199-1209. PMID: 32273246.
      Citations: 6     Fields:    Translation:Humans
    62. Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Larson RA, Lipton JH, Mayer J, Pane F, Radich JP, Richter J, Rosti G, Rousselot P, Saglio G, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hochhaus A, Kim DW, Mahon FX, Nicolini F, Niederwieser D, Rea D, Saußele S, Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 04; 34(4):966-984. PMID: 32127639; PMCID: PMC7214240.
      Citations: 399     Fields:    Translation:Humans
    63. Cahill KE, Karimi YH, Karrison TG, Jain N, Green M, Weiner H, Fulton N, Kadri S, Godley LA, Artz AS, Liu H, Thirman MJ, Le Beau MM, McNerney ME, Segal J, Larson RA, Stock W, Odenike O. A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Adv. 2020 02 25; 4(4):599-606. PMID: 32074275; PMCID: PMC7042987.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    64. Marcucci G, Geyer S, Laumann K, Zhao W, Bucci D, Uy GL, Blum W, Eisfeld AK, Pardee TS, Wang ES, Stock W, Kolitz JE, Kohlschmidt J, Bloomfield CD, Stone RM, Larson RA, Mrózek K. Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Adv. 2020 02 25; 4(4):696-705. PMID: 32092139; PMCID: PMC7042984.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    65. Wang AY, Kline J, Stock W, Kosuri S, Artz A, Larson RA, Riedell PA, Bishop M, Liu H. Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 05; 26(5):1025-1027. PMID: 32018063.
      Citations: 14     Fields:    Translation:Humans
    66. Thiede C, Jahn N, Panina E, Gambietz A, Larson RA, Prior TW, Marcucci G, Jones D, Heuser M, Nomdedeu JF, Mandrekar SJ, Klisovic RB, Wei AH, Sierra J, Brandwein JM, de Witte T, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Serve H, Ehninger G, Gathmann I, Benner A, Pallaud C, Stone RM, Bloomfield CD, Döhner K, Krauter J, Voso MT, Ottone T, Sanz MA, Amadori S, Döhner H. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. 2020 01 30; 135(5):371-380. PMID: 31826241; PMCID: PMC6993016.
      Citations: 69     Fields:    Translation:HumansCells
    67. Kothari S, Artz AS, Lee SM, Fulton N, Park JH, Stock W, Larson RA, Odenike O, Kline J, LaBelle J, Kosuri S, Riedell P, Nakamura Y, Bishop MR, Liu H. Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. Bone Marrow Transplant. 2020 06; 55(6):1161-1168. PMID: 31992847.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    68. Pagel JM, Othus M, Garcia-Manero G, Fang M, Radich JP, Rizzieri DA, Marcucci G, Strickland SA, Litzow MR, Savoie ML, Spellman SR, Confer DL, Chell JW, Brown M, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Bayer RL, Larson RA, Stone RM, Claxton D, Essell J, Luger SM, Mohan SR, Moseley A, Erba HP, Appelbaum FR. Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. JCO Oncol Pract. 2020 06; 16(6):e464-e475. PMID: 32048933; PMCID: PMC7291544.
      Citations: 8     Fields:    Translation:Humans
    69. Saygin C, Kishtagari A, Cassaday RD, Reizine N, Yurkiewicz I, Liedtke M, Stock W, Larson RA, Levine RL, Tallman MS, Park JH, Kerr C, Przychodzen B, Sekeres MA, Kalaycio ME, Carraway HE, Hamilton BK, Sobecks R, Gerds A, Mukherjee S, Nazha A, Maciejewski JP, Advani AS. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 2019 12 23; 3(24):4228-4237. PMID: 31869410; PMCID: PMC6929388.
      Citations: 14     Fields:    Translation:Humans
    70. Derman BA, Kordas K, Ridgeway J, Chow S, Dale W, Lee SM, Aguada E, Jakubowiak AJ, Jasielec J, Kline J, Kosuri S, Larson RA, Liu H, Mortel M, Odenike O, Pisano J, Riedell P, Stock W, Bishop MR, Artz AS. Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019 11 26; 3(22):3488-3498. PMID: 31725894; PMCID: PMC6880895.
      Citations: 22     Fields:    Translation:Humans
    71. Smith CC, Levis MJ, Perl AE, Martinelli G, Neubauer A, Berman E, Montesinos P, Baer MR, Larson RA, Chou WC, Yokoyama H, Recher C, Yoon SS, Hill JE, Rosales M, Bahceci E. Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial. Blood. 2019 Nov 13; 134(Supplement_1):14. PMID: 31723984.
      Citations:    
    72. Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 10 31; 381(18):1728-1740. PMID: 31665578.
      Citations: 425     Fields:    Translation:HumansCTClinical Trials
    73. Klepin HD, Ritchie E, Major-Elechi B, Le-Rademacher J, Seisler D, Storrick L, Sanford BL, Marcucci G, Zhao W, Geyer SA, Ballman KV, Powell BL, Baer MR, Stock W, Cohen HJ, Stone RM, Larson RA, Uy GL. Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). J Geriatr Oncol. 2020 01; 11(1):107-113. PMID: 31668825; PMCID: PMC6943189.
      Citations: 20     Fields:    Translation:Humans
    74. Derman BA, Larson RA. Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach? Best Pract Res Clin Haematol. 2019 12; 32(4):101102. PMID: 31779969; PMCID: PMC6903406.
      Citations: 4     Fields:    Translation:Humans
    75. DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, Deangelo DJ, Kebriaei P, Rowe JM, Seftel MD, Stock W, Tallman MS, Fanning S, Inamoto Y, Kansagra A, Johnston L, Nagler A, Sauter CS, Savani BN, Perales MA, Carpenter PA, Larson RA, Weisdorf D. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019 11; 25(11):2113-2123. PMID: 31446198.
      Citations: 30     Fields:    Translation:Humans
    76. Jabbour EJ, Kantarjian HM, Thomas X, Larson RA, Yoon SS, Ghobadi A, Topp MS, Tran Q, Franklin JL, Forman SJ, Stein AS, Gökbuget N. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer. 2019 Dec 01; 125(23):4181-4192. PMID: 31433496.
      Citations: 13     Fields:    Translation:Humans
    77. Yin J, LaPlant B, Uy GL, Marcucci G, Blum W, Larson RA, Stone RM, Mandrekar SJ. Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). Blood Adv. 2019 06 11; 3(11):1714-1721. PMID: 31171508; PMCID: PMC6560345.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    78. Ustun C, Le-Rademacher J, Wang HL, Othus M, Sun Z, Major B, Zhang MJ, Storrick E, Lafky JM, Chow S, Attar EC, Nand S, Bloomfield CD, Cripe LD, Tallman MS, Appelbaum F, Larson RA, Marcucci G, Roboz GJ, Uy GL, Stone RM, Jatoi A, Shea TC, de Lima M, Foran JM, Sandmaier BM, Litzow MR, Erba HP, Hurria A, Weisdorf DJ, Artz AS, Mrózek K. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019 11; 33(11):2599-2609. PMID: 31073153; PMCID: PMC6842042.
      Citations: 37     Fields:    Translation:Humans
    79. Flynn KE, Mauro MJ, George G, Hinman A, Baim A, Kota V, Larson RA, Lipton JH, Thompson JE, Wadleigh M, Atallah E. Patients' perspectives on the definition of cure in chronic myeloid leukemia. Leuk Res. 2019 05; 80:40-42. PMID: 30955853.
      Citations: 3     Fields:    Translation:Humans
    80. Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM, Larson RA, Mrózek K. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019 04 04; 133(14):1548-1559. PMID: 30658992; PMCID: PMC6450431.
      Citations: 125     Fields:    Translation:HumansCellsCTClinical Trials
    81. Fan Y, Artz AS, van Besien K, Stock W, Larson RA, Odenike O, Godley LA, Kline J, Cunningham JM, LaBelle JL, Bishop MR, Liu H. Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant. Exp Hematol Oncol. 2019; 8:1. PMID: 30622841; PMCID: PMC6317199.
      Citations: 6     
    82. Hantel A, Larson RA. Imatinib is still recommended for frontline therapy for CML. Blood Adv. 2018 12 26; 2(24):3648-3652. PMID: 30587493; PMCID: PMC6306882.
      Citations: 7     Fields:    Translation:Humans
    83. Roboz GJ, Mandrekar SJ, Desai P, Laumann K, Walker AR, Wang ES, Kolitz JE, Powell BL, Attar EC, Stock W, Bloomfield CD, Kohlschmidt J, Hassane DC, Garraway L, Baltay M, Tracy A, Marcucci G, Stone RM, Larson RA, Mrózek K, Jané-Valbuena J. Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Adv. 2018 12 26; 2(24):3608-3617. PMID: 30567725; PMCID: PMC6306886.
      Citations: 27     Fields:    Translation:Humans
    84. Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018 12 27; 379(26):2517-2528. PMID: 30501481; PMCID: PMC6325637.
      Citations: 328     Fields:    Translation:HumansCTClinical Trials
    85. Kutny MA, Geyer S, Laumann KM, Gregory J, Willman CL, Stock W, Larson RA, Powell BL, Feusner JH. Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance). Pediatr Blood Cancer. 2019 03; 66(3):e27542. PMID: 30393935; PMCID: PMC6392047.
      Citations: 6     Fields:    Translation:Humans
    86. Osman AEG, Anderson J, Churpek JE, Christ TN, Curran E, Godley LA, Liu H, Thirman MJ, Odenike T, Stock W, Larson RA. Treatment of Acute Promyelocytic Leukemia in Adults. J Oncol Pract. 2018 11; 14(11):649-657. PMID: 30423270.
      Citations: 23     Fields:    Translation:Humans
    87. D'Angelo CR, Novitsky B, Mee Lee S, Godley LA, Kline J, Larson RA, Liu H, Odenike O, Stock W, Bishop MR, Artz AS. Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2019 03; 60(3):629-638. PMID: 30070150.
      Citations: 2     Fields:    Translation:Humans
    88. Byrd JC, Ruppert AS, Heerema NA, Halvorson AE, Hoke E, Smith MR, Godwin JE, Couban S, Fehniger TA, Thirman MJ, Tallman MS, Appelbaum FR, Stone RM, Robinson S, Chang JE, Mandrekar SJ, Larson RA. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv. 2018 07 24; 2(14):1705-1718. PMID: 30030269; PMCID: PMC6058242.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    89. Stein AS, Larson RA, Schuh AC, Stevenson W, Lech-Maranda E, Tran Q, Zimmerman Z, Kormany W, Topp MS. Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. Blood Adv. 2018 07 10; 2(13):1522-1531. PMID: 29954814; PMCID: PMC6039663.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    90. Cheng JX, Chen L, Li Y, Cloe A, Yue M, Wei J, Watanabe KA, Shammo JM, Anastasi J, Shen QJ, Larson RA, He C, Le Beau MM, Vardiman JW. Author Correction: RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat Commun. 2018 06 06; 9(1):2286. PMID: 29875356; PMCID: PMC5989218.
      Citations: 7     Fields:    
    91. Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC Cancer. 2018 04 02; 18(1):359. PMID: 29609532; PMCID: PMC5879565.
      Citations: 8     Fields:    Translation:Humans
    92. Cheng JX, Chen L, Li Y, Cloe A, Yue M, Wei J, Watanabe KA, Shammo JM, Anastasi J, Shen QJ, Larson RA, He C, Le Beau MM, Vardiman JW. RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat Commun. 2018 03 21; 9(1):1163. PMID: 29563491; PMCID: PMC5862959.
      Citations: 100     Fields:    Translation:HumansCells
    93. Stone RM, Manley PW, Larson RA, Capdeville R. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv. 2018 02 27; 2(4):444-453. PMID: 29487059; PMCID: PMC5858474.
      Citations: 59     Fields:    Translation:Humans
    94. Liu H, Zha Y, Choudhury N, Malnassy G, Fulton N, Green M, Park JH, Nakamura Y, Larson RA, Salazar AM, Odenike O, Gajewski TF, Stock W. WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. Exp Hematol Oncol. 2018; 7:1. PMID: 29344432; PMCID: PMC5765712.
      Citations: 11     
    95. Wang AY, Weiner H, Green M, Chang H, Fulton N, Larson RA, Odenike O, Artz AS, Bishop MR, Godley LA, Thirman MJ, Kosuri S, Churpek JE, Curran E, Pettit K, Stock W, Liu H. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol. 2018 01 05; 11(1):4. PMID: 29304833; PMCID: PMC5756334.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    96. Tsai SB, Rhodes J, Liu H, Shore T, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz AS. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004. PMID: 29288821.
      Citations: 7     Fields:    Translation:Humans
    97. Larson RA, Stone RM, Döhner H. Midostaurin in FLT3-Mutated Acute Myeloid Leukemia. N Engl J Med. 2017 11 09; 377(19):1903. PMID: 29117486.
      Citations: 22     Fields:    Translation:Humans
    98. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017 08 03; 377(5):454-464. PMID: 28644114; PMCID: PMC5754190.
      Citations: 849     Fields:    Translation:HumansCTClinical Trials
    99. Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Ustun C, Wang ES, Stuart R, Martinelli G, Bahceci E, Levis M, Tibes R, Röllig C, Neubauer A. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017 08; 18(8):1061-1075. PMID: 28645776; PMCID: PMC5572576.
      Citations: 227     Fields:    Translation:HumansCellsCTClinical Trials
    100. Muus P, Kantarjian H, Lyons RM, Larson RA, Sekeres MA, Becker PS, Orejudos A, Franklin J, Fenaux P. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. Br J Haematol. 2017 09; 178(6):906-913. PMID: 28616874; PMCID: PMC5600084.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    101. Larson RA. Managing CNS disease in adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2018 01; 59(1):3-13. PMID: 28535095.
      Citations: 30     Fields:    Translation:Humans
    102. IRIS Investigators, Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017 03 09; 376(10):917-927. PMID: 28273028; PMCID: PMC5901965.
      Citations: 436     Fields:    Translation:Humans
    103. Knoebel RW, Larson RA. Pepsi® or Coke®? Influence of acid on dasatinib absorption. J Oncol Pharm Pract. 2018 Mar; 24(2):156-158. PMID: 29284366.
      Citations: 5     Fields:    Translation:Humans
    104. Khan N, Hantel A, Knoebel RW, Artz A, Larson RA, Godley LA, Thirman MJ, Liu H, Churpek JE, King D, Odenike O, Stock W. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-7. PMID: 28278716.
      Citations: 11     Fields:    Translation:Humans
    105. Uy GL, Mandrekar SJ, Laumann K, Marcucci G, Zhao W, Levis MJ, Klepin HD, Baer MR, Powell BL, Westervelt P, DeAngelo DJ, Stock W, Sanford B, Blum WG, Bloomfield CD, Stone RM, Larson RA. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv. 2017 Jan 24; 1(5):331-340. PMID: 29034366; PMCID: PMC5637402.
      Citations: 29     Fields:    
    106. Mantha S, Goldman DA, Devlin SM, Lee JW, Zannino D, Collins M, Douer D, Iland HJ, Litzow MR, Stein EM, Appelbaum FR, Larson RA, Stone R, Powell BL, Geyer S, Laumann K, Rowe JM, Erba H, Coutre S, Othus M, Park JH, Wiernik PH, Tallman MS. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood. 2017 Mar 30; 129(13):1763-1767. PMID: 28082441; PMCID: PMC5374291.
      Citations: 36     Fields:    Translation:Humans
    107. Li Z, Weng H, Su R, Weng X, Zuo Z, Li C, Huang H, Nachtergaele S, Dong L, Hu C, Qin X, Tang L, Wang Y, Hong GM, Huang H, Wang X, Chen P, Gurbuxani S, Arnovitz S, Li Y, Li S, Strong J, Neilly MB, Larson RA, Jiang X, Zhang P, Jin J, He C, Chen J. FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase. Cancer Cell. 2017 01 09; 31(1):127-141. PMID: 28017614; PMCID: PMC5234852.
      Citations: 710     Fields:    Translation:HumansCells
    108. Cortes J, Talpaz M, Smith HP, Snyder DS, Khoury J, Bhalla KN, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian HM, Rosen O, Van Etten RA. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. 2017 03; 102(3):519-528. PMID: 27927766; PMCID: PMC5394958.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    109. Estey E, Grimwade D, Appelbaum FR, Ebert BL, Larson RA, Levine RL, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Bloomfield CD, Döhner H, Amadori S, Büchner T, Dombret H, Fenaux P, Lo-Coco F, Löwenberg B. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 01 26; 129(4):424-447. PMID: 27895058; PMCID: PMC5291965.
      Citations: 2316     Fields:    Translation:Humans
    110. Stock W, Diouf B, Crews KR, Pei D, Cheng C, Laumann K, Mandrekar SJ, Luger S, Advani A, Stone RM, Larson RA, Evans WE. An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther. 2017 03; 101(3):391-395. PMID: 27618250; PMCID: PMC5320866.
      Citations: 25     Fields:    Translation:Humans
    111. Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, Kanojia D, Yoshida K, Ganesan S, Hattori N, Fulton N, Tan KT, Alpermann T, Kuo MC, Rostami S, Matthews J, Sanada M, Liu LZ, Shiraishi Y, Miyano S, Chendamarai E, Hou HA, Malnassy G, Ma T, Garg M, Ding LW, Sun QY, Chien W, Ikezoe T, Lill M, Biondi A, Larson RA, Powell BL, Chng WJ, Tien HF, Heuser M, Ganser A, Koren-Michowitz M, Kornblau SM, Kantarjian HM, Nowak D, Hofmann WK, Yang H, Stock W, Ghavamzadeh A, Alimoghaddam K, Haferlach T, Ogawa S, Shih LY, Mathews V, Koeffler HP, Lübbert M. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia. 2016 12; 30(12):2430. PMID: 27713533; PMCID: PMC7609306.
      Citations: 16     Fields:    
    112. Baljevic M, Dumitriu B, Lee JW, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM, Appelbaum FR, Powell BL, Larson RA, Lancet J, Litzow MR, Luger SM, Young NS, Tallman MS, Coutré SE. Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia. Acta Haematol. 2016; 136(4):210-218. PMID: 27632567; PMCID: PMC5198772.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    113. Mullane KM, Nuss C, Ridgeway J, Prichard MN, Hartline CB, Theusch J, Mommeja-Marin H, Larson RA. Brincidofovir treatment of acyclovir-resistant disseminated varicella zoster virus infection in an immunocompromised host. Transpl Infect Dis. 2016 Oct; 18(5):785-790. PMID: 27481400.
      Citations: 6     Fields:    Translation:HumansCells
    114. Blum W, Sanford BL, Klisovic R, DeAngelo DJ, Uy G, Powell BL, Stock W, Baer MR, Kolitz JE, Wang ES, Hoke E, Kohlschmidt J, Bloomfield CD, Geyer S, Marcucci G, Stone RM, Larson RA, Alliance for Clinical Trials in Oncology, Mrózek K. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). Leukemia. 2017 01; 31(1):34-39. PMID: 27624549; PMCID: PMC5214595.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    115. Rojek K, Nickels E, Neistadt B, Marquez R, Wickrema A, Artz A, van Besien K, Larson RA, Lee MK, Segal JP, King MC, Walsh T, Shimamura A, Keel SB, Churpek JE, Godley LA. Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Biol Blood Marrow Transplant. 2016 11; 22(11):2100-2103. PMID: 27497531; PMCID: PMC5592729.
      Citations: 21     Fields:    Translation:Humans
    116. Jiang X, Bugno J, Hu C, Yang Y, Qi J, Chen P, Gurbuxani S, Arnovitz S, Strong J, Ferchen K, Ulrich B, Weng H, Wang Y, Huang H, Li S, Neilly MB, Larson RA, Le Beau MM, Bohlander SK, Jin J, Li Z, Bradner JE, Hong S, Chen J, Herold T. Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles. Cancer Res. 2016 08 01; 76(15):4470-80. PMID: 27280396; PMCID: PMC4970973.
      Citations: 26     Fields:    Translation:HumansAnimals
    117. Debeb BG, Lacerda L, Larson R, Wolfe AR, Krishnamurthy S, Reuben JM, Ueno NT, Gilcrease M, Woodward WA. Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget. 2016 May 10; 7(19):28329-39. PMID: 27078845; PMCID: PMC5053589.
      Citations: 26     Fields:    Translation:HumansCells
    118. Kantarjian HM, Stein AS, Grande Garcia C, Larson RA, Stelljes M, Zugmaier G, Benjamin JE, Zhang A, Jia C, Bargou RC, Gökbuget N, Topp MS. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. Cancer. 2016 07 15; 122(14):2178-85. PMID: 27143254.
      Citations: 29     Fields:    Translation:Humans
    119. Jiang X, Hu C, Arnovitz S, Bugno J, Yu M, Zuo Z, Chen P, Huang H, Ulrich B, Gurbuxani S, Weng H, Strong J, Wang Y, Li Y, Salat J, Li S, Elkahloun AG, Yang Y, Neilly MB, Larson RA, Le Beau MM, Bohlander SK, Liu PP, Zhang J, Li Z, He C, Jin J, Hong S, Chen J, Herold T. miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nat Commun. 2016 04 26; 7:11452. PMID: 27116251; PMCID: PMC5477496.
      Citations: 79     Fields:    Translation:HumansAnimalsCells
    120. Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, Kanojia D, Yoshida K, Ganesan S, Hattori N, Fulton N, Tan KT, Alpermann T, Kuo MC, Rostami S, Matthews J, Sanada M, Liu LZ, Shiraishi Y, Miyano S, Chendamarai E, Hou HA, Malnassy G, Ma T, Garg M, Ding LW, Sun QY, Chien W, Ikezoe T, Lill M, Biondi A, Larson RA, Powell BL, Chng WJ, Tien HF, Heuser M, Ganser A, Koren-Michowitz M, Kornblau SM, Kantarjian HM, Nowak D, Hofmann WK, Yang H, Stock W, Ghavamzadeh A, Alimoghaddam K, Haferlach T, Ogawa S, Shih LY, Mathews V, Koeffler HP, Lübbert M. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia. 2016 08; 30(8):1672-81. PMID: 27063598; PMCID: PMC4972641.
      Citations: 50     Fields:    Translation:Humans
    121. Alachkar H, Fulton N, Sanford B, Malnassy G, Mutonga M, Larson RA, Bloomfield CD, Marcucci G, Nakamura Y, Stock W. Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. Pharmacogenomics J. 2017 06; 17(3):274-279. PMID: 27019981; PMCID: PMC5089920.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    122. Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, Eigendorff E, Guilhot J, Guilhot F, Mahon FX, Martinelli G, Mayer J, Niederwieser D, Saussele S, Schiffer CA, Silver RT, Simonsson B, Conti RM, Müller MC. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. J Natl Cancer Inst. 2016 Jul; 108(7). PMID: 26944912; PMCID: PMC4948567.
      Citations: 37     Fields:    Translation:Humans
    123. Tsai SB, Liu H, Shore T, Fan Y, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Martinez G, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz AS. Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant. 2016 06; 22(6):1065-1072. PMID: 26912055; PMCID: PMC4867292.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    124. DeBoer R, Koval G, Mulkey F, Wetzler M, Devine S, Marcucci G, Stone RM, Larson RA, Bloomfield CD, Geyer S, Mullighan CG, Stock W. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma. 2016 10; 57(10):2298-306. PMID: 26892479; PMCID: PMC5008253.
      Citations: 17     Fields:    Translation:HumansCells
    125. van Besien K, Hari P, Zhang MJ, Liu HT, Stock W, Godley L, Odenike O, Larson R, Bishop M, Wickrema A, Gergis U, Mayer S, Shore T, Tsai S, Rhodes J, Cushing MM, Korman S, Artz A. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 05; 101(5):634-43. PMID: 26869630; PMCID: PMC5004373.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    126. Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM, Hochhaus A, le Coutre PD, Etienne G, Dorlhiac-Llacer PE. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016 05; 30(5):1044-54. PMID: 26837842; PMCID: PMC4858585.
      Citations: 314     Fields:    Translation:Humans
    127. D'Angelo CR, Kocherginsky M, Pisano J, Bishop MR, Godley LA, Kline J, Larson RA, Liu H, Odenike O, Stock W, Artz AS. Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. Leuk Lymphoma. 2016 08; 57(8):1807-13. PMID: 26699199.
      Citations: 7     Fields:    Translation:HumansCells
    128. Churpek JE, Marquez R, Neistadt B, Claussen K, Lee MK, Churpek MM, Huo D, Weiner H, Bannerjee M, Godley LA, Le Beau MM, Pritchard CC, Walsh T, King MC, Olopade OI, Larson RA. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. 2016 Jan 15; 122(2):304-11. PMID: 26641009; PMCID: PMC4707981.
      Citations: 56     Fields:    Translation:Humans
    129. Castillo JJ, Mulkey F, Geyer S, Kolitz JE, Blum W, Powell BL, George SL, Larson RA, Stone RM. Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials. Am J Hematol. 2016 Feb; 91(2):199-204. PMID: 26526191; PMCID: PMC4724329.
      Citations: 27     Fields:    Translation:Humans
    130. Larson RA. Is there a best TKI for chronic phase CML? Blood. 2015 Nov 19; 126(21):2370-5. PMID: 26585806.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    131. Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, Champlin RE, Chen YB, Vij R, Slack J, Soiffer RJ, Larson RA, Shea TC, Hars V, Sibley AB, Giralt S, Carter S, Horowitz MM, Linker C, Alyea EP. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015 Dec 10; 33(35):4167-75. PMID: 26527780; PMCID: PMC4658453.
      Citations: 74     Fields:    Translation:HumansCTClinical Trials
    132. Li Z, Chen P, Su R, Li Y, Hu C, Wang Y, Arnovitz S, He M, Gurbuxani S, Zuo Z, Elkahloun AG, Li S, Weng H, Huang H, Neilly MB, Wang S, Olson EN, Larson RA, Le Beau MM, Zhang J, Jiang X, Wei M, Jin J, Liu PP, Chen J. Overexpression and knockout of miR-126 both promote leukemogenesis. Blood. 2015 Oct 22; 126(17):2005-15. PMID: 26361793; PMCID: PMC4616234.
      Citations: 50     Fields:    Translation:HumansAnimalsCells
    133. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. PMID: 26211600; PMCID: PMC5365030.
      Citations: 51     Fields:    Translation:Humans
    134. Voorhees PM, Orlowski RZ, Mulkey F, Watson P, Geyer S, Sanford BL, Bennett E, Chanan-Khan AA, Bloomfield CD, Larson RA. Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol. 2015 Nov; 171(3):373-7. PMID: 26202857; PMCID: PMC5569902.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    135. Lucas DM, Ruppert AS, Lozanski G, Dewald GW, Lozanski A, Claus R, Plass C, Flinn IW, Neuberg DS, Paietta EM, Bennett JM, Jelinek DF, Gribben JG, Hussein MA, Appelbaum FR, Larson RA, Moore DF, Tallman MS, Byrd JC, Grever MR. Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997. Leuk Lymphoma. 2015; 56(11):3031-7. PMID: 25721902; PMCID: PMC4688910.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    136. Conti RM, Padula WV, Larson RA. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU. Ann Hematol. 2015 Apr; 94 Suppl 2:S249-57. PMID: 25814091; PMCID: PMC4598066.
      Citations: 12     Fields:    Translation:HumansAnimals
    137. Li Z, Onel K, Sukhanova M, Mirza MK, Yap KL, Borinets O, Larson RA, Stock W, Sasaki MM, Joseph L, Raca G, Stölzel F. Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma. Leukemia. 2015 Oct; 29(10):2113-6. PMID: 25787914; PMCID: PMC4575593.
      Citations: 15     Fields:    Translation:Humans
    138. DiPersio JF, Erba HP, Larson RA, Luger SM, Tallman MS, Brill JM, Vuagniaux G, Rouits E, Sorensen JM, Zanna C. Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study. Clin Lymphoma Myeloma Leuk. 2015 Jul; 15(7):443-9. PMID: 25842225; PMCID: PMC5028895.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    139. Lanasa MC, Andritsos L, Brown JR, Gabrilove J, Larson RA, Kipps TJ, Milligan DW, Janssens A, Johnson AJ, Heerema NA, Stilgenbauer S, Devin J, Hallek M, Byrd JC, Grever MR, Caligaris-Cappio F, Ghia P, Leblond V, Bühler A. Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Res. 2015 May; 39(5):495-500. PMID: 25804339; PMCID: PMC4557608.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    140. Larson RA. Is there a best TKI for chronic phase CML? Hematology Am Soc Hematol Educ Program. 2015; 2015:250-6. PMID: 26637730.
      Citations: 2     Fields:    Translation:Humans
    141. Othus M, Appelbaum FR, Petersdorf SH, Kopecky KJ, Slovak M, Nevill T, Brandwein J, Larson RA, Stiff PJ, Walter RB, Tallman MS, Stenke L, Erba HP. Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant. 2015 Mar; 21(3):559-64. PMID: 25536215; PMCID: PMC4386840.
      Citations: 26     Fields:    Translation:Humans
    142. Stein AS, Zugmaier G, O'Brien S, Fielding AK, Heffner L, Larson RA, Litzow M, Ribera JM, Rambaldi A, Schiller G, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM, Topp MS, Gökbuget N, Bargou RC, Dombret H, Neumann S, Foà R, Brüggemann M. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015 Jan; 16(1):57-66. PMID: 25524800.
      Citations: 517     Fields:    Translation:HumansCTClinical Trials
    143. Odenike O, Halpern A, Godley LA, Madzo J, Karrison T, Green M, Fulton N, Mattison RJ, Yee KW, Bennett M, Koval G, Malnassy G, Larson RA, Ratain MJ, Stock W. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9. PMID: 25483416; PMCID: PMC4390421.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    144. Guinn D, Ruppert AS, Maddocks K, Jaglowski S, Gordon A, Lin TS, Larson R, Marcucci G, Hertlein E, Woyach J, Johnson AJ, Byrd JC. miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. Leukemia. 2015 May; 29(5):1210-3. PMID: 25486872; PMCID: PMC4424166.
      Citations: 10     Fields:    Translation:Humans
    145. Wang X, Owzar K, Gupta P, Larson RA, Mulkey F, Miller AA, Lewis LD, Hurd D, Vij R, Ratain MJ, Murry DJ, Alliance for Clinical Trials in Oncology. Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). Br J Clin Pharmacol. 2014 Nov; 78(5):1005-13. PMID: 24838014; PMCID: PMC4243874.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    146. Padula WV, Conti R, Larson R. What is the Most Cost-Effective Strategy for Treating Chronic Myeloid Leukemia After Imatinib Loses Patent Exclusivity in Europe? Value Health. 2014 Nov; 17(7):A636. PMID: 27202269.
      Citations: 3     Fields:    
    147. Niederwieser C, Kohlschmidt J, Volinia S, Whitman SP, Metzeler KH, Eisfeld AK, Maharry K, Yan P, Frankhouser D, Becker H, Schwind S, Carroll AJ, Nicolet D, Mendler JH, Curfman JP, Wu YZ, Baer MR, Powell BL, Kolitz JE, Moore JO, Carter TH, Bundschuh R, Larson RA, Stone RM, Marcucci G, Bloomfield CD, Mrózek K. Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia. 2015 Mar; 29(3):567-75. PMID: 25204569; PMCID: PMC4351165.
      Citations: 44     Fields:    Translation:HumansCells
    148. Beumer JH, Owzar K, Lewis LD, Jiang C, Holleran JL, Christner SM, Blum W, Devine S, Kolitz JE, Linker C, Vij R, Alyea EP, Larson RA, Ratain MJ, Egorin MJ. Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol. 2014 Nov; 74(5):927-38. PMID: 25163570; PMCID: PMC4210372.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    149. Zabriskie MS, Eide CA, Tantravahi SK, Estrada J, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Druker BJ, Deininger MW, O'Hare T, Vellore NA, Nicolini FE, Hernández-Boluda JC, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Baron R. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014 Sep 08; 26(3):428-442. PMID: 25132497; PMCID: PMC4160372.
      Citations: 146     Fields:    Translation:HumansCells
    150. Jasielec JK, Larson RA. Dasatinib-Related Pulmonary Toxicity Mimicking an Atypical Infection. J Clin Oncol. 2016 Feb 20; 34(6):e46-8. PMID: 24958829.
      Citations: 5     Fields:    Translation:Humans
    151. McNerney ME, Brown CD, Peterson AL, Banerjee M, Larson RA, Anastasi J, Le Beau MM, White KP. The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q). Br J Haematol. 2014 Aug; 166(4):550-6. PMID: 24931631; PMCID: PMC5479678.
      Citations: 15     Fields:    Translation:HumansCells
    152. Mirza MK, Sukhanova M, Onel K, Larson RA, Stock W, Ehninger G, Kuithan F, Reddy P, Joseph L, Raca G, Stölzel F, Zöphel K. Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays. Leuk Res. 2014 Sep; 38(9):1091-6. PMID: 25088808; PMCID: PMC4157130.
      Citations: 5     Fields:    Translation:Humans
    153. Lacerda L, Reddy JP, Liu D, Larson R, Li L, Masuda H, Brewer T, Debeb BG, Xu W, Buchholz TA, Ueno NT, Woodward WA, Hortobágyi GN. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. Stem Cells Transl Med. 2014 Jul; 3(7):849-56. PMID: 24833589; PMCID: PMC4073823.
      Citations: 41     Fields:    Translation:HumansCells
    154. Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, Kline J, Liu H, Odenike OM, Larson RA, van Besien K, Artz AS. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014 Aug; 99(8):1373-9. PMID: 24816237; PMCID: PMC4116837.
      Citations: 94     Fields:    Translation:Humans
    155. von Keudell G, Larson RA. Positron Emission Tomography-Computed Tomography Imaging of a Patient With Several Myeloid Sarcomas With FLT3-ITD and NPM1 Mutations. J Clin Oncol. 2016 05 01; 34(13):e123-5. PMID: 24733791.
      Citations: 1     Fields:    Translation:HumansCells
    156. Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FR. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol. 2014 May; 165(4):497-503. PMID: 24528179; PMCID: PMC4064464.
      Citations: 16     Fields:    Translation:HumansAnimals
    157. Hughes TP, Kantarjian HM, Cervantes F, Niederwieser D, Rosti G, Ossenkoppele G, Lobo C, Shibayama H, Fan X, Menssen HD, Kemp C, Larson RA, Saglio G, Hochhaus A, Guilhot F, le Coutre PD. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica. 2014 Jul; 99(7):1204-11. PMID: 24532039; PMCID: PMC4077082.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    158. Greim H, Kaden DA, Larson RA, Palermo CM, Rice JM, Ross D, Snyder R. The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment. Ann N Y Acad Sci. 2014 Mar; 1310:7-31. PMID: 24495159; PMCID: PMC4002179.
      Citations: 19     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    159. Moser BK, Gallagher RE, Laumann K, Bloomfield CD, Powell BL, Koval G, Gulati K, Holowka N, Larson RA, Tallman MS, Appelbaum FR, Sher D, Willman C, Paietta E, Stock W, Poiré X. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma. 2014 Jul; 55(7):1523-32. PMID: 24160850; PMCID: PMC4273565.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    160. Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Blum KA, Powell BL, Shea TC, Nattam S, Hoke E, Cheson BD, Larson RA, Alliance for Clinical Trials In Oncology (ACTION). Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol. 2014 Apr; 165(1):102-11. PMID: 24428673; PMCID: PMC3996561.
      Citations: 31     Fields:    Translation:Humans
    161. Kolitz JE, George SL, Benson DM, Maharry K, Marcucci G, Vij R, Powell BL, Allen SL, Deangelo DJ, Shea TC, Stock W, Bakan CE, Hars V, Hoke E, Bloomfield CD, Caligiuri MA, Larson RA, Alliance for Clinical Trials in Oncology. Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer. 2014 Apr 01; 120(7):1010-7. PMID: 24382782; PMCID: PMC4139069.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    162. Erba HP, Othus M, Walter RB, Kirschbaum MH, Tallman MS, Larson RA, Slovak ML, Kopecky KJ, Gundacker HM, Appelbaum FR. Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res. 2014 Mar; 38(3):329-33. PMID: 24411921; PMCID: PMC4247790.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    163. Hughes TP, Saglio G, Kantarjian HM, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A, Guilhot F. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014 Feb 27; 123(9):1353-60. PMID: 24335106; PMCID: PMC4624459.
      Citations: 103     Fields:    Translation:HumansCells
    164. Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, Emanuel PD, Tallman M, Wadleigh M, Larson RA, Lipton JH, Slovak ML, Appelbaum FR, Druker BJ. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol. 2014 Jan; 164(2):223-32. PMID: 24383843; PMCID: PMC4127316.
      Citations: 27     Fields:    Translation:HumansCellsCTClinical Trials
    165. Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8. PMID: 24178622; PMCID: PMC4310865.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    166. Wetzler M, Kohlschmidt J, Pilorge S, Krug U, Carroll AJ, Larson RA, Marcucci G, Hiddemann W, Bloomfield CD, Mrózek K, Dombret H, Döhner H, Büchner T. Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. Haematologica. 2014 Feb; 99(2):308-13. PMID: 24097631; PMCID: PMC3912961.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    167. Churpek JE, Larson RA. The evolving challenge of therapy-related myeloid neoplasms. Best Pract Res Clin Haematol. 2013 Dec; 26(4):309-17. PMID: 24507808; PMCID: PMC3920194.
      Citations: 29     Fields:    Translation:HumansCells
    168. Wetzler M, Watson D, Stock W, Koval G, Mulkey FA, Hoke EE, McCarty JM, Blum WG, Powell BL, Marcucci G, Bloomfield CD, Linker CA, Larson RA. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica. 2014 Jan; 99(1):111-5. PMID: 24077846; PMCID: PMC4007937.
      Citations: 34     Fields:    Translation:Humans
    169. Woods WG, Franklin AR, Alonzo TA, Gerbing RB, Donohue KA, Othus M, Horan J, Appelbaum FR, Estey EH, Bloomfield CD, Larson RA. Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials. Cancer. 2013 Dec 01; 119(23):4170-9. PMID: 24104597; PMCID: PMC3833872.
      Citations: 18     Fields:    Translation:Humans
    170. Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Martinelli G, Mayer J, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Baccarani M, Guilhot F, Mahon FX, Müller MC, Saußele S, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug 08; 122(6):872-84. PMID: 23803709; PMCID: PMC4915804.
      Citations: 716     Fields:    Translation:Humans
    171. Chen P, Price C, Li Z, Li Y, Cao D, Wiley A, He C, Gurbuxani S, Kunjamma RB, Huang H, Jiang X, Arnovitz S, Xu M, Hong GM, Elkahloun AG, Neilly MB, Wunderlich M, Larson RA, Le Beau MM, Mulloy JC, Liu PP, Rowley JD, Chen J. miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. Proc Natl Acad Sci U S A. 2013 Jul 09; 110(28):11511-6. PMID: 23798388; PMCID: PMC3710804.
      Citations: 62     Fields:    Translation:Humans
    172. Locke F, Agarwal R, Kunnavakkam R, van Besien K, Larson RA, Odenike O, Godley LA, Liu H, Le Beau MM, Gurbuxani S, Thirman MJ, Sipkins D, White C, Artz A, Stock W. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant. 2013 Nov; 48(11):1437-43. PMID: 23771005; PMCID: PMC4279870.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    173. Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM, Larson RA, Alliance for Clinical Trials in Oncology. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs. 2013 Oct; 31(5):1311-20. PMID: 23700288; PMCID: PMC3773017.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    174. Jones JA, Ruppert AS, Zhao W, Lin TS, Rai K, Peterson B, Larson RA, Marcucci G, Heerema NA, Byrd JC. Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101. Leuk Lymphoma. 2013 Dec; 54(12):2654-9. PMID: 23547837; PMCID: PMC3766417.
      Citations: 4     Fields:    Translation:Humans
    175. Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, Larson RA, Erba HP, Stiff PJ, Stuart RK, Walter RB, Tallman MS, Stenke L, Appelbaum FR. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013 Jun 13; 121(24):4854-60. PMID: 23591789; PMCID: PMC3682338.
      Citations: 266     Fields:    Translation:HumansCTClinical Trials
    176. Lin RJ, Larson RA, van Besien K, Rich ES. Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Myeloid Leukemia following Orthotopic Cardiac Transplantation. Case Rep Hematol. 2013; 2013:140138. PMID: 23607004; PMCID: PMC3625539.
      Citations:    
    177. Saglio G, Larson RA, Kim DW, Etienne G, Rosti G, De Souza C, Kurokawa M, Kalaycio ME, Hoenekopp A, Fan X, Shou Y, Kantarjian HM, Hughes TP, Hochhaus A. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2013 May 02; 121(18):3703-8. PMID: 23502220; PMCID: PMC4915803.
      Citations: 45     Fields:    Translation:HumansCellsCTClinical Trials
    178. Jain N, Liu H, Artz AS, Anastasi J, Odenike O, Godley LA, Joseph L, Marino S, Kline J, Nguyen V, Schouten V, Kunnavakkam R, Larson RA, Stock W, Ulaszek J, Savage PA, Wickrema A, van Besien K. Immune reconstitution after combined haploidentical and umbilical cord blood transplant. Leuk Lymphoma. 2013 Jun; 54(6):1242-9. PMID: 23088744.
      Citations: 11     Fields:    Translation:HumansCells
    179. Li Z, Herold T, He C, Valk PJ, Chen P, Jurinovic V, Mansmann U, Radmacher MD, Maharry KS, Sun M, Yang X, Huang H, Jiang X, Sauerland MC, Hiddemann W, Elkahloun A, Neilly MB, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Bullinger L, Liu PP, Delwel R, Marcucci G, Lowenberg B, Bloomfield CD, Rowley JD, Bohlander SK, Chen J, Büchner T, Döhner K. Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol. 2013 Mar 20; 31(9):1172-81. PMID: 23382473; PMCID: PMC3595425.
      Citations: 100     Fields:    Translation:Humans
    180. Woyach JA, Ruppert AS, Rai K, Lin TS, Geyer S, Kolitz J, Appelbaum FR, Tallman MS, Belch AR, Morrison VA, Larson RA, Byrd JC. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J Clin Oncol. 2013 Feb 01; 31(4):440-7. PMID: 23233702; PMCID: PMC3731920.
      Citations: 12     Fields:    Translation:Humans
    181. Wang ES, Lyons RM, Larson RA, Gandhi S, Liu D, Matei C, Scott B, Hu K, Yang AS. A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol. 2012 Nov 29; 5:71. PMID: 23190430; PMCID: PMC3520696.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    182. Schwind S, Edwards CG, Nicolet D, Maharry K, Wu YZ, Paschka P, Eisfeld AK, Hoellerbauer P, Becker H, Metzeler KH, Curfman J, Kohlschmidt J, Prior TW, Kolitz JE, Blum W, Pettenati MJ, Dal Cin P, Carroll AJ, Caligiuri MA, Larson RA, Volinia S, Marcucci G, Bloomfield CD, Alliance for Clinical Trials in Oncology, Mrózek K. inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. Blood. 2013 Jan 10; 121(2):385-91. PMID: 23160462; PMCID: PMC3544117.
      Citations: 16     Fields:    Translation:HumansCells
    183. Ottmann OG, Larson RA, Kantarjian HM, le Coutre PD, Baccarani M, Hochhaus A, Kim DW, Fan X, Novick S, Giles FJ. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia. Leukemia. 2013 Jun; 27(6):1411-3. PMID: 23138184.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    184. Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 2013 Apr; 27(4):907-13. PMID: 23174881; PMCID: PMC4140185.
      Citations: 7     Fields:    Translation:Humans
    185. Jiang X, Huang H, Li Z, He C, Li Y, Chen P, Gurbuxani S, Arnovitz S, Hong GM, Price C, Ren H, Kunjamma RB, Neilly MB, Salat J, Wunderlich M, Slany RK, Zhang Y, Larson RA, Le Beau MM, Mulloy JC, Rowley JD, Chen J. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia. Proc Natl Acad Sci U S A. 2012 Nov 20; 109(47):19397-402. PMID: 23132946; PMCID: PMC3511140.
      Citations: 61     Fields:    Translation:HumansAnimalsCells
    186. Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhees P, Wang ES, Blum W, Stone RM, Marcucci G, Bloomfield CD, Moser B, Larson RA. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2013 Mar 01; 31(7):923-9. PMID: 23129738; PMCID: PMC3577952.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    187. Kantarjian HM, Larson RA, Deering KL, Mauro MJ, Cortés JE. Current practices in the management of chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):48-54. PMID: 23103085; PMCID: PMC3645375.
      Citations: 2     Fields:    Translation:Humans
    188. Jiang X, Huang H, Li Z, Li Y, Wang X, Gurbuxani S, Chen P, He C, You D, Zhang S, Wang J, Arnovitz S, Elkahloun A, Price C, Hong GM, Ren H, Kunjamma RB, Neilly MB, Matthews JM, Xu M, Larson RA, Le Beau MM, Slany RK, Liu PP, Lu J, Zhang J, He C, Chen J. Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell. 2012 Oct 16; 22(4):524-35. PMID: 23079661; PMCID: PMC3480215.
      Citations: 112     Fields:    Translation:HumansAnimalsCells
    189. Muffly L, Larson RA. Improving outcomes in childhood T-cell acute lymphoblastic leukemia: promising results from the Children's Oncology Group incorporating nelarabine into front-line therapy. Transl Pediatr. 2012 Oct; 1(2):120-2. PMID: 26835275; PMCID: PMC4728878.
      Citations: 5     
    190. Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP, Metzeler KH, Schwind S, Wu YZ, Kohlschmidt J, Pettenati MJ, Heerema NA, Block AW, Patil SR, Baer MR, Kolitz JE, Moore JO, Carroll AJ, Stone RM, Larson RA, Bloomfield CD, Mrózek K. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012 Dec 20; 30(36):4515-23. PMID: 22987078; PMCID: PMC3518729.
      Citations: 194     Fields:    Translation:Humans
    191. Ravandi F, Estey EH, Appelbaum FR, Lo-Coco F, Schiffer CA, Larson RA, Burnett AK, Kantarjian HM. Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol. 2012 Nov 10; 30(32):3921-3. PMID: 22987091; PMCID: PMC4874205.
      Citations: 40     Fields:    Translation:Humans
    192. Solh M, Rai KR, Peterson BL, Kolitz JE, Appelbaum FR, Tallman MS, Belch A, Larson RA, Morrison VA. The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). Leuk Lymphoma. 2013 Feb; 54(2):252-4. PMID: 22897733; PMCID: PMC5639695.
      Citations: 16     Fields:    Translation:Humans
    193. Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Deininger M, Druker BJ. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012 Nov 08; 120(19):3898-905. PMID: 22915637; PMCID: PMC3496952.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    194. Raca G, Larson RA. Acute myeloid leukemia: the challenge of unfavorable cytogenetics. Oncology (Williston Park). 2012 Aug; 26(8):724, 726-7. PMID: 22957405.
      Citations:    Fields:    Translation:Humans
    195. Kaminska EC, Larson RA, Petronic-Rosic V. Amelanocytic anhidrotic alopecia areata-like phenotype after allogeneic hematopoietic cell transplant. Arch Dermatol. 2012 Aug; 148(8):931-4. PMID: 22911189.
      Citations: 3     Fields:    Translation:Humans
    196. Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013 Jan; 27(1):107-12. PMID: 22763385.
      Citations: 78     Fields:    Translation:HumansCTClinical Trials
    197. Mendler JH, Maharry K, Radmacher MD, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD, Mrózek K. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol. 2012 Sep 01; 30(25):3109-18. PMID: 22753902; PMCID: PMC3732007.
      Citations: 123     Fields:    Translation:HumansCTClinical Trials
    198. Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, Westervelt P, Marcucci G, DeAngelo DJ, Vardiman JW, McDonnell D, Bloomfield CD, Larson RA, Mrózek K. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 2013 Jan 01; 119(1):90-8. PMID: 22744771; PMCID: PMC4220742.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    199. Gallagher RE, Moser BK, Racevskis J, Bloomfield CD, Carroll AJ, Ketterling RP, Roulston D, Schachter-Tokarz E, Zhou DC, Chen IM, Harvey R, Koval G, Sher DA, Feusner JH, Tallman MS, Larson RA, Powell BL, Appelbaum FR, Paietta E, Willman CL, Stock W, Poiré X. Treatment-influenced associations of PML-RARa mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood. 2012 Sep 06; 120(10):2098-108. PMID: 22734072; PMCID: PMC3437597.
      Citations: 31     Fields:    Translation:Humans
    200. Lozanski G, Ruppert AS, Heerema NA, Lozanski A, Lucas DM, Gordon A, Gribben JG, Morrison VA, Rai KM, Marcucci G, Larson RA, Byrd JC. Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study. Leuk Lymphoma. 2012 Sep; 53(9):1743-8. PMID: 22369572; PMCID: PMC3724930.
      Citations: 9     Fields:    Translation:HumansCells
    201. Yin OQ, Giles FJ, Baccarani M, le Coutre P, Chiparus O, Gallagher N, Saglio G, Hughes TP, Hochhaus A, Kantarjian HM, Larson RA. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2012 Aug; 70(2):345-50. PMID: 22623211; PMCID: PMC5557057.
      Citations: 7     Fields:    Translation:Humans
    202. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, Flinn IW, Kurokawa M, Moiraghi B, Yu R, Blakesley RE, Gallagher NJ, Saglio G, Kantarjian HM. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012 Oct; 26(10):2197-203. PMID: 22699418.
      Citations: 151     Fields:    Translation:Humans
    203. Larson RA. Cytogenetics, not just previous therapy, determines the course of therapy-related myeloid neoplasms. J Clin Oncol. 2012 Jul 01; 30(19):2300-2. PMID: 22585693.
      Citations: 13     Fields:    Translation:Humans
    204. Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu L, Zucknick M, Mertens D, Oakes CC, Larson RA, Kay NE, Jelinek DF, Kipps TJ, Rassenti LZ, Gribben JG, Heerema NA, Marcucci G, Plass C, Byrd JC, Bühler A, Döhner H. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol. 2012 Jul 10; 30(20):2483-91. PMID: 22564988; PMCID: PMC3397783.
      Citations: 63     Fields:    Translation:HumansCells
    205. Richa EM, Kunnavakkam R, Godley LA, Kline J, Odenike O, Larson RA, Nguyen V, Stock W, Wickrema A, Van Besien K, Artz AS. Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy. 2012 Jul; 14(6):707-15. PMID: 22548695.
      Citations: 4     Fields:    Translation:Humans
    206. Eisfeld AK, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Whitman SP, Metzeler KH, Mendler JH, Wu YZ, Liyanarachchi S, Patel R, Baer MR, Powell BL, Carter TH, Moore JO, Kolitz JE, Wetzler M, Caligiuri MA, Larson RA, Tanner SM, de la Chapelle A, Bloomfield CD, Mrózek K. miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood. 2012 Jul 12; 120(2):249-58. PMID: 22529287; PMCID: PMC3398762.
      Citations: 40     Fields:    Translation:Humans
    207. Larson SM, Campbell NP, Huo D, Artz A, Zhang Y, Gajria D, Green M, Weiner H, Daugherty C, Odenike O, Godley LA, Hyjek E, Gurbuxani S, Thirman M, Sipkins D, Van Besien K, Larson RA, Stock W. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50. PMID: 21913806.
      Citations: 6     Fields:    Translation:Humans
    208. Kutny MA, Moser BK, Laumann K, Feusner JH, Gamis A, Gregory J, Larson RA, Powell BL, Stock W, Willman CL, Woods WG, Meshinchi S. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Oct; 59(4):662-7. PMID: 22378655; PMCID: PMC3368997.
      Citations: 26     Fields:    Translation:Humans
    209. Whitman SP, Caligiuri MA, Maharry K, Radmacher MD, Kohlschmidt J, Becker H, Wu YZ, Schwind S, Metzeler KH, Mendler JH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Larson RA, Marcucci G, Bloomfield CD, Mrózek K. The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia. Leukemia. 2012 Jul; 26(7):1713-7. PMID: 22382894; PMCID: PMC3565839.
      Citations: 7     Fields:    Translation:HumansCells
    210. Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Bloomfield CD, Mrózek K. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012 Mar 01; 30(7):742-50. PMID: 22291079; PMCID: PMC3295550.
      Citations: 128     Fields:    Translation:Humans
    211. Li Z, Huang H, Li Y, Jiang X, Chen P, Arnovitz S, Radmacher MD, Maharry K, Elkahloun A, Yang X, He C, He M, Zhang Z, Dohner K, Neilly MB, Price C, Lussier YA, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Bullinger L, Valk PJ, Delwel R, Lowenberg B, Liu PP, Marcucci G, Bloomfield CD, Rowley JD, Chen J. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood. 2012 Mar 08; 119(10):2314-24. PMID: 22251480; PMCID: PMC3311258.
      Citations: 95     Fields:    Translation:HumansCells
    212. Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP, Kantarjian HM, le Coutre PD. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 2012 May; 68(5):723-33. PMID: 22207416; PMCID: PMC5557053.
      Citations: 30     Fields:    Translation:Humans
    213. Giles FJ, Kantarjian HM, le Coutre PD, Baccarani M, Mahon FX, Blakesley RE, Gallagher NJ, Gillis K, Goldberg SL, Larson RA, Hochhaus A, Ottmann OG. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia. 2012 May; 26(5):959-62. PMID: 22157807.
      Citations: 28     Fields:    Translation:Humans
    214. van Besien K, Stock W, Rich E, Odenike O, Godley LA, O'Donnell PH, Kline J, Nguyen V, Del Cerro P, Larson RA, Artz AS. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Jun; 18(6):913-21. PMID: 22079470; PMCID: PMC3423318.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    215. Larson RA. CML: live long and prosper. Blood. 2011 Oct 27; 118(17):4499-500. PMID: 22033940.
      Citations:    Fields:    Translation:Humans
    216. Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP, Wu YZ, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD, Mrózek K. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 2011 Dec 22; 118(26):6920-9. PMID: 22031865; PMCID: PMC3245212.
      Citations: 135     Fields:    Translation:Humans
    217. Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S, Kline J, Nguyen V, Cunningham J, Larson RA, del Cerro P, Schroeder L, Pape L, Stock W, Wickrema A, Artz AS, van Besien K. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011 Dec 08; 118(24):6438-45. PMID: 21976674; PMCID: PMC3236125.
      Citations: 68     Fields:    Translation:HumansCellsCTClinical Trials
    218. Oliansky DM, Larson RA, Weisdorf D, Dillon H, Ratko TA, Wall D, McCarthy PL, Hahn T. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review. Biol Blood Marrow Transplant. 2012 Jan; 18(1):16-7. PMID: 21963620.
      Citations: 8     Fields:    Translation:Humans
    219. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011 Sep; 12(9):841-51. PMID: 21856226.
      Citations: 189     Fields:    Translation:HumansCellsCTClinical Trials
    220. Schwind S, Marcucci G, Kohlschmidt J, Radmacher MD, Maharry K, Becker H, Metzeler KH, Whitman SP, Wu YZ, Powell BL, Baer MR, Kolitz JE, Carroll AJ, Larson RA, Caligiuri MA, Bloomfield CD, Mrózek K. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood. 2011 Oct 13; 118(15):4188-98. PMID: 21828125; PMCID: PMC3291490.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    221. Oliansky DM, Larson RA, Weisdorf D, Dillon H, Ratko TA, Wall D, McCarthy PL, Hahn T. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review. Biol Blood Marrow Transplant. 2012 Jan; 18(1):18-36.e6. PMID: 21803017.
      Citations: 18     Fields:    Translation:Humans
    222. Smith MR, Neuberg D, Flinn IW, Grever MR, Lazarus HM, Rowe JM, Dewald G, Bennett JM, Paietta EM, Byrd JC, Hussein MA, Appelbaum FR, Larson RA, Litzow MR, Tallman MS. Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Blood. 2011 Sep 29; 118(13):3525-7. PMID: 21803850; PMCID: PMC3186330.
      Citations: 20     Fields:    Translation:Humans
    223. Larson RA, Le Beau MM. Prognosis and therapy when acute promyelocytic leukemia and other "good risk" acute myeloid leukemias occur as a therapy-related myeloid neoplasm. Mediterr J Hematol Infect Dis. 2011; 3(1):e2011032. PMID: 21869918; PMCID: PMC3152454.
      Citations: 17     
    224. Farag SS, Maharry K, Zhang MJ, George SL, DiPersio J, Bunjes DW, Marcucci G, Baer MR, Cairo M, Copelan E, Cutler CS, Isola L, Lazarus HM, Litzow MR, Marks DI, Rizzieri DA, Soiffer R, Larson RA, Tallman MS, Bloomfield CD, Weisdorf DJ, Acute Leukemia Committee of the Center for International Blood and Marrow Transplant Research and Ca, Pérez WS, Mrózek K, Ringdén O. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1796-803. PMID: 21699879; PMCID: PMC3817558.
      Citations: 48     Fields:    Translation:HumansCTClinical Trials
    225. Becker H, Maharry K, Radmacher MD, Metzeler KH, Whitman SP, Schwind S, Kohlschmidt J, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Marcucci G, Bloomfield CD, Mrózek K. Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Haematologica. 2011 Oct; 96(10):1488-95. PMID: 21659357; PMCID: PMC3186310.
      Citations: 9     Fields:    Translation:Humans
    226. Stoddart A, McNerney ME, Bartom E, Bergerson R, Young DJ, Qian Z, Wang J, Fernald AA, Davis EM, Larson RA, White KP, Le Beau MM. Genetic pathways leading to therapy-related myeloid neoplasms. Mediterr J Hematol Infect Dis. 2011; 3(1):e2011019. PMID: 21713073; PMCID: PMC3113274.
      Citations: 12     
    227. Buyse M, Squifflet P, Lange BJ, Alonzo TA, Larson RA, Kolitz JE, George SL, Bloomfield CD, Castaigne S, Chevret S, Blaise D, Maraninchi D, Lucchesi KJ, Burzykowski T. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood. 2011 Jun 30; 117(26):7007-13. PMID: 21518931; PMCID: PMC3539044.
      Citations: 27     Fields:    Translation:HumansPHPublic Health
    228. Odenike O, Thirman MJ, Artz AS, Godley LA, Larson RA, Stock W. Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol. 2011 Apr; 38(2):196-214. PMID: 21421110.
      Citations: 12     Fields:    Translation:Humans
    229. Godley LA, Cunningham J, Dolan ME, Huang RS, Gurbuxani S, McNerney ME, Larson RA, Leong H, Lussier Y, Onel K, Odenike O, Stock W, White KP, Le Beau MM. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol. 2011 Apr; 38(2):215-24. PMID: 21421111; PMCID: PMC5591437.
      Citations: 5     Fields:    Translation:HumansCells
    230. Metzeler KH, Maharry K, Radmacher MD, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD, Mrózek K. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2011 Apr 01; 29(10):1373-81. PMID: 21343549; PMCID: PMC3084003.
      Citations: 148     Fields:    Translation:HumansCTClinical Trials
    231. Baer MR, George SL, Sanford BL, Kolitz JE, Moore JO, Stone RM, Powell BL, Caligiuri MA, Bloomfield CD, Larson RA, Cancer and Leukemia Group B, Mrózek K. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia. 2011 May; 25(5):800-7. PMID: 21321569; PMCID: PMC3821040.
      Citations: 18     Fields:    Translation:Humans
    232. Woyach JA, Ruppert AS, Heerema NA, Peterson BL, Gribben JG, Morrison VA, Rai KR, Larson RA, Byrd JC. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011 Apr 01; 29(10):1349-55. PMID: 21321292; PMCID: PMC3084002.
      Citations: 52     Fields:    Translation:Humans
    233. Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Shou Y, Gallagher NJ, Blakesley R, Baccarani M, Cortes J, le Coutre PD. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011 Jan 27; 117(4):1141-5. PMID: 21098399; PMCID: PMC4916554.
      Citations: 118     Fields:    Translation:HumansCTClinical Trials
    234. Schwind S, Maharry K, Radmacher MD, Holland KB, Margeson D, Whitman SP, Hickey C, Becker H, Metzeler KH, Paschka P, Baldus CD, Liu S, Garzon R, Powell BL, Kolitz JE, Carroll AJ, Caligiuri MA, Larson RA, Marcucci G, Bloomfield CD, Mrózek K. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010 Dec 20; 28(36):5257-64. PMID: 21079133; PMCID: PMC3018359.
      Citations: 97     Fields:    Translation:Humans
    235. O'Donnell PH, Artz AS, Undevia SD, Pai RK, Del Cerro P, Horowitz S, Godley LA, Hart J, Innocenti F, Larson RA, Odenike OM, Stock W, Van Besien K. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010 Dec; 51(12):2240-9. PMID: 20919852; PMCID: PMC4477684.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    236. Bhatta S, Kut V, Petronic-Rosic V, Hyjek E, Larson RA. Therapy-related myeloid sarcoma with an NPM1 mutation. Leuk Lymphoma. 2010 Nov; 51(11):2130-1. PMID: 20858094.
      Citations: 1     Fields:    Translation:Humans
    237. Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, Gonzalez J, Feusner JH, Gonzalez M, Gallagher R, Miguel JD, Larson RA, Milone G, Paietta E, Rayon C, Rowe JM, Rivas C, Schiffer CA, Vellenga E, Shepherd L, Slack JL, Wiernik PH, Willman CL, Sanz MA. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood. 2010 Dec 16; 116(25):5650-9. PMID: 20858857; PMCID: PMC3031411.
      Citations: 14     Fields:    Translation:Humans
    238. Schwind S, Marcucci G, Maharry K, Radmacher MD, Holland KB, Margeson D, Becker H, Whitman SP, Wu YZ, Metzeler KH, Powell BL, Kolitz JE, Carter TH, Moore JO, Baer MR, Carroll AJ, Caligiuri MA, Larson RA, Bloomfield CD, Mrózek K. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010 Dec 16; 116(25):5660-9. PMID: 20841507; PMCID: PMC3031412.
      Citations: 58     Fields:    Translation:Humans
    239. Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11; 116(19):3751-7. PMID: 20705755; PMCID: PMC2981533.
      Citations: 132     Fields:    Translation:Humans
    240. Lin TS, Donohue KA, Byrd JC, Lucas MS, Hoke EE, Bengtson EM, Rai KR, Atkins JN, Link BK, Larson RA. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol. 2010 Oct 10; 28(29):4500-6. PMID: 20697069; PMCID: PMC2988639.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    241. Stone RM, Moser B, Sanford B, Schulman P, Kolitz JE, Allen S, Stock W, Galinsky I, Vij R, Marcucci G, Hurd D, Larson RA, Cancer and Leukemia Group B. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res. 2011 Mar; 35(3):329-33. PMID: 20688393; PMCID: PMC3023007.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    242. Hughes TP, Hochhaus A, Branford S, Kaeda JS, Foroni L, Druker BJ, Larson RA, O'Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP, IRIS investigators, Müller MC, Guilhot F. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010 Nov 11; 116(19):3758-65. PMID: 20679528; PMCID: PMC3266053.
      Citations: 165     Fields:    Translation:Humans
    243. Whitman SP, Maharry K, Radmacher MD, Becker H, Margeson D, Holland KB, Wu YZ, Schwind S, Metzeler KH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Moore JO, Stone RM, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD, Mrózek K. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010 Nov 04; 116(18):3622-6. PMID: 20656931; PMCID: PMC2981481.
      Citations: 109     Fields:    Translation:Humans
    244. Fernandes MS, Reddy MM, Croteau NJ, Walz C, Weisbach H, Podar K, Band H, Carroll M, Reiter A, Larson RA, Salgia R, Griffin JD, Sattler M. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem. 2010 Oct 15; 285(42):32596-605. PMID: 20622007; PMCID: PMC2952262.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    245. Walter RB, Appelbaum FR, Tallman MS, Weiss NS, Larson RA, Estey EH. Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood. 2010 Oct 07; 116(14):2420-8. PMID: 20538802; PMCID: PMC2953881.
      Citations: 32     Fields:    Translation:Humans
    246. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM, ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 Jun 17; 362(24):2251-9. PMID: 20525993.
      Citations: 566     Fields:    Translation:HumansCTClinical Trials
    247. Giles FJ, Abruzzese E, Rosti G, Kim DW, Bhatia R, Bosly A, Goldberg S, Kam GL, Jagasia M, Mendrek W, Fischer T, Facon T, Marin D, Mueller MC, Shou Y, Gallagher NJ, Larson RA, Mahon FX, Baccarani M, Cortes J, Kantarjian HM, Dünzinger U. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia. 2010 Jul; 24(7):1299-301. PMID: 20520639; PMCID: PMC3078756.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    248. Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, DeAngelo DJ, Shea TC, Stock W, Baer MR, Hars V, Maharry K, Hoke E, Vardiman JW, Bloomfield CD, Larson RA, Cancer and Leukemia Group B. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010 Sep 02; 116(9):1413-21. PMID: 20522709; PMCID: PMC2938834.
      Citations: 57     Fields:    Translation:Humans
    249. Godley LA, Njiaju UO, Green M, Weiner H, Lin S, Odenike O, Rich ES, Artz A, Van Besien K, Daugherty CK, Zhang Y, Le Beau MM, Stock W, Larson RA. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma. 2010 Jun; 51(6):995-1006. PMID: 20536346.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    250. Becker H, Marcucci G, Maharry K, Radmacher MD, Margeson D, Whitman SP, Paschka P, Holland KB, Schwind S, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Bloomfield CD, Mrózek K. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010 Aug 05; 116(5):788-92. PMID: 20442368; PMCID: PMC2918333.
      Citations: 46     Fields:    Translation:Humans
    251. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD, Mrózek K. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010 May 10; 28(14):2348-55. PMID: 20368543; PMCID: PMC2881719.
      Citations: 335     Fields:    Translation:Humans
    252. Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G, Müller MC. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010 Mar; 85(3):164-70. PMID: 20131302.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    253. Becker H, Marcucci G, Maharry K, Radmacher MD, Margeson D, Whitman SP, Wu YZ, Schwind S, Paschka P, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD, Mrózek K. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol. 2010 Feb 01; 28(4):596-604. PMID: 20026798; PMCID: PMC2815994.
      Citations: 148     Fields:    Translation:Humans
    254. Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010 Jan 20; 28(3):437-44. PMID: 20008626.
      Citations: 48     Fields:    Translation:HumansCTClinical Trials
    255. Qian Z, Joslin JM, Tennant TR, Reshmi SC, Young DJ, Stoddart A, Larson RA, Le Beau MM. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Chem Biol Interact. 2010 Mar 19; 184(1-2):50-7. PMID: 19958752; PMCID: PMC4642715.
      Citations: 37     Fields:    Translation:HumansAnimals
    256. Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R, European LeukemiaNet, Baccarani M, Guilhot F. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009 Dec 10; 27(35):6041-51. PMID: 19884523; PMCID: PMC4979100.
      Citations: 413     Fields:    Translation:Humans
    257. Mattison RJ, Larson RA. Role of allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia. Curr Opin Oncol. 2009 Nov; 21(6):601-8. PMID: 19713843.
      Citations: 1     Fields:    Translation:Humans
    258. van Besien K, Dew A, Lin S, Joseph L, Godley LA, Larson RA, Odenike T, Rich E, Stock W, Wickrema A, Artz AS. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009 Nov; 50(11):1809-17. PMID: 19821799.
      Citations: 25     Fields:    Translation:Humans
    259. Estey EH, Amadori S, Appelbaum FR, Burnett AK, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Bloomfield CD, European LeukemiaNet, Döhner H, Büchner T, Dombret H, Löwenberg B. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010 Jan 21; 115(3):453-74. PMID: 19880497.
      Citations: 1361     Fields:    Translation:Humans
    260. Larson RA. Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemia. Chem Biol Interact. 2010 Mar 19; 184(1-2):21-5. PMID: 19822134; PMCID: PMC2846194.
      Citations: 6     Fields:    Translation:HumansAnimals
    261. Byrd JC, Peterson BL, Rai KR, Hurd D, Hohl R, Perry MC, Gockerman J, Nattam S, Larson RA. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leuk Lymphoma. 2009 Oct; 50(10):1589-96. PMID: 19863336.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    262. Druker B, Larson RA, Gathmann I, So C, Waltzman R, O'Brien SG, Guilhot F. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica. 2009 Dec; 94(12):1669-75. PMID: 19648168; PMCID: PMC2791923.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    263. Mattison R, Larson RA. Discontinuing imatinib in chronic myeloid leukemia: don't try this at home. Leuk Lymphoma. 2009 Jun; 50(6):868-70. PMID: 19455466.
      Citations: 1     Fields:    Translation:Humans
    264. Apperley JF, Cortes JE, Kim DW, Roy L, Roboz GJ, Rosti G, Bullorsky EO, Abruzzese E, Hochhaus A, Heim D, de Souza CA, Larson RA, Lipton JH, Khoury HJ, Kim HJ, Sillaber C, Hughes TP, Erben P, Van Tornout J, Stone RM. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol. 2009 Jul 20; 27(21):3472-9. PMID: 19487385; PMCID: PMC4979080.
      Citations: 57     Fields:    Translation:HumansCTClinical Trials
    265. Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P, Whitman SP, Baldus CD, Vij R, Powell BL, Carroll AJ, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD, Mrózek K. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2009 Jul 01; 27(19):3198-204. PMID: 19451432; PMCID: PMC2716941.
      Citations: 64     Fields:    Translation:Humans
    266. Raza A, Galili N, Callander N, Ochoa L, Piro L, Emanuel P, Williams S, Burris H, Faderl S, Estrov Z, Curtin P, Larson RA, Keck JG, Jones M, Meng L, Brown GL. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol. 2009 May 13; 2:20. PMID: 19439093; PMCID: PMC2694211.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    267. Larson RA. Therapy-related myeloid neoplasms. Haematologica. 2009 Apr; 94(4):454-9. PMID: 19336749; PMCID: PMC2663607.
      Citations: 26     Fields:    Translation:Humans
    268. Knight JA, Skol AD, Shinde A, Hastings D, Walgren RA, Shao J, Tennant TR, Banerjee M, Allan JM, Le Beau MM, Larson RA, Graubert TA, Cox NJ, Onel K. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood. 2009 May 28; 113(22):5575-82. PMID: 19299336; PMCID: PMC2689055.
      Citations: 36     Fields:    Translation:Humans
    269. Linker CA, Owzar K, Powell B, Hurd D, Damon LE, Archer LE, Larson RA, Cancer and Leukemia Group B. Auto-SCT for AML in second remission: CALGB study 9620. Bone Marrow Transplant. 2009 Sep; 44(6):353-9. PMID: 19289999.
      Citations: 14     Fields:    Translation:Humans
    270. O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA, IRIS Investigators, Hochhaus A, Müller MC. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009 Jun; 23(6):1054-61. PMID: 19282833.
      Citations: 313     Fields:    Translation:HumansCTClinical Trials
    271. Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, Krahnke T, Cortes J, Druker BJ, International Randomized Study of Interferon and STI571 (IRIS) Investigators. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 2009 Feb 01; 115(3):551-60. PMID: 19117345; PMCID: PMC4445370.
      Citations: 31     Fields:    
    272. Larson RA. Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in CML. Clin Adv Hematol Oncol. 2009 Feb; 7(2):S3-5. PMID: 19391309.
      Citations: 1     Fields:    Translation:Humans
    273. Artz A, Larson RA, Kline J, Odenike O, Rich E, Godley L, Stock W, van Besien K, Poiré X. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma. 2009 Jan; 50(1):85-91. PMID: 19142796; PMCID: PMC3617055.
      Citations: 6     Fields:    Translation:Humans
    274. Larson RA. Allogeneic hematopoietic cell transplantation is not recommended for all adults with standard-risk acute lymphoblastic leukemia in first complete remission. Biol Blood Marrow Transplant. 2009 Jan; 15(1 Suppl):11-6. PMID: 19147070.
      Citations: 6     Fields:    Translation:Humans
    275. Grinblatt DL, Yu D, Hars V, Vardiman JW, Powell BL, Nattam S, Silverman LR, de Castro C, Stone RM, Bloomfield CD, Larson RA, Cancer and Leukemia Group. Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). Cancer. 2009 Jan 01; 115(1):84-93. PMID: 19025972; PMCID: PMC2887616.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    276. Artz AS, Wickrema A, Dinner S, Godley LA, Kocherginsky M, Odenike O, Rich ES, Stock W, Ulaszek J, Larson RA, van Besien K. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1209-16. PMID: 18940674; PMCID: PMC2668514.
      Citations: 37     Fields:    Translation:Humans
    277. Odenike OM, Alkan S, Sher D, Godwin JE, Huo D, Brandt SJ, Green M, Xie J, Zhang Y, Vesole DH, Stiff P, Wright J, Larson RA, Stock W. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res. 2008 Nov 01; 14(21):7095-101. PMID: 18981008; PMCID: PMC4498482.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    278. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, Chen P, Wang Y, Yan M, Qian Z, Neilly MB, Jin J, Zhang Y, Bohlander SK, Zhang DE, Larson RA, Le Beau MM, Thirman MJ, Golub TR, Rowley JD, Chen J. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A. 2008 Oct 07; 105(40):15535-40. PMID: 18832181; PMCID: PMC2563085.
      Citations: 218     Fields:    Translation:HumansAnimals
    279. Marcucci G, Maharry K, Radmacher MD, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD, Mrózek K. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol. 2008 Nov 01; 26(31):5078-87. PMID: 18809607; PMCID: PMC2652095.
      Citations: 161     Fields:    Translation:Humans
    280. Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland MC, Heinecke A, Radmacher M, Marcucci G, Whitman SP, Maharry K, Paschka P, Larson RA, Berdel WE, Mansmann U, Hiddemann W, Bohlander SK, Buske C, Cancer and Leukemia Group B, German AML Cooperative Group, Metzeler KH, Büchner T, Wörmann B. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 2008 Nov 15; 112(10):4193-201. PMID: 18716133; PMCID: PMC2954679.
      Citations: 220     Fields:    Translation:HumansCTClinical Trials
    281. Stone RM, Donohue KA, Stock W, Hars V, Linker CA, Shea T, Deangelo DJ, Marcucci G, Bloomfield CD, Larson RA, Cancer and Leukemia Group B. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol. 2009 Apr; 63(5):859-64. PMID: 18670778.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    282. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol. 2008 Aug; 35(4):418-29. PMID: 18692692; PMCID: PMC2600445.
      Citations: 115     Fields:    Translation:Humans
    283. Larson R. Allogeneic hematopoietic cell transplantation for adults with ALL. Bone Marrow Transplant. 2008 Aug; 42 Suppl 1:S18-S24. PMID: 18724292.
      Citations: 2     Fields:    Translation:Humans
    284. Wetzler M, Donohue KA, Odenike OM, Feldman EJ, Hurd DD, Stone RM, Westerfelt P, Bloomfield CD, Larson RA. Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107. Leuk Lymphoma. 2008 Jul; 49(7):1274-8. PMID: 18452072; PMCID: PMC4137465.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    285. Baer MR, George SL, Caligiuri MA, Sanford BL, Bothun SM, Kolitz JE, Powell BL, Moore JO, Stone RM, Anastasi J, Bloomfield CD, Larson RA, Mrózek K. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol. 2008 Oct 20; 26(30):4934-9. PMID: 18591543; PMCID: PMC2652081.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    286. Paschka P, Marcucci G, Ruppert AS, Whitman SP, Maharry K, Langer C, Baldus CD, Zhao W, Powell BL, Baer MR, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD, Mrózek K. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2008 Oct 01; 26(28):4595-602. PMID: 18559874; PMCID: PMC2653131.
      Citations: 99     Fields:    Translation:Humans
    287. Neubauer A, Maharry K, Thiede C, Marcucci G, Paschka P, Mayer RJ, Larson RA, Liu ET, Bloomfield CD, Mrózek K. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol. 2008 Oct 01; 26(28):4603-9. PMID: 18559876; PMCID: PMC2653132.
      Citations: 57     Fields:    Translation:Humans
    288. Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, Larson RA, Nachman J, Children's Cancer Group, Cancer and Leukemia Group B studies. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008 Sep 01; 112(5):1646-54. PMID: 18502832; PMCID: PMC2518876.
      Citations: 172     Fields:    Translation:HumansCTClinical Trials
    289. le Coutre P, Giles FJ, Apperley J, Ottmann OG, Larson RA, Haque A, Gallagher N, Rosti G, Cortes JE, Kantarjian HM. Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or -intolerance: Update of a phase II study. J Clin Oncol. 2008 May 20; 26(15_suppl):7050. PMID: 27949591.
      Citations:    
    290. Odenike O, Green M, Larson RA, Rich ES, Ott J, Ratain MJ, Stock W. Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms. J Clin Oncol. 2008 May 20; 26(15_suppl):7057. PMID: 27949624.
      Citations:    
    291. Stock W, Najib K, Moser BK, Powell BL, Holowka N, Gulati K, Bloomfield CD, Larson RA, Sher D. High incidence of FLT3 mutations in adults with Acute Promyelocytic Leukemia (APL): Correlation with diagnostic features and treatment outcome (CALGB 9710). J Clin Oncol. 2008 May 20; 26(15_suppl):7002. PMID: 27949960.
      Citations:    
    292. Giles FJ, Larson RA, Kantarjian HM, le Coutre P, Palandri F, Haque A, Gallagher N, Ottmann OG. Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib. J Clin Oncol. 2008 May 20; 26(15_suppl):7017. PMID: 27950021.
      Citations:    
    293. Marcucci G, Radmacher MD, Maharry K, Ruppert AS, Paschka P, Vukosavljevic T, Whitman SP, Baldus CD, Langer C, Liu CG, Carroll AJ, Powell BL, Garzon R, Croce CM, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD, Mrózek K. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008 May 01; 358(18):1919-28. PMID: 18450603.
      Citations: 203     Fields:    Translation:Humans
    294. Ellis NA, Huo D, Yildiz O, Worrillow LJ, Banerjee M, Le Beau MM, Larson RA, Allan JM, Onel K. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood. 2008 Aug 01; 112(3):741-9. PMID: 18426989; PMCID: PMC2481552.
      Citations: 32     Fields:    Translation:Humans
    295. Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, Rich E, Borthakur G, Godley L, Verstovsek S, Artz A, Wierda W, Larson RA, Zhang Y, Cortes J, Ratain MJ, Giles FJ. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008 Aug; 26(4):331-8. PMID: 18425419; PMCID: PMC4905709.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    296. Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Ezzeddine R, Countouriotis AM, Kantarjian HM, Hochhaus A, Müller MC. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008 Jun; 22(6):1200-6. PMID: 18401416.
      Citations: 123     Fields:    Translation:Humans
    297. Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Baldus CD, Vukosavljevic T, Liu CG, Ross ME, Powell BL, de la Chapelle A, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD, Cancer and Leukemia Group B (CALGB), Mrózek K. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood. 2008 Jun 01; 111(11):5371-9. PMID: 18378853; PMCID: PMC2396728.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    298. Gordon MK, Sher D, Karrison T, Kebriaei P, Chuang K, Zhang Y, McDonnell D, Artz A, Godley L, Odenike O, Rich E, Michaelis L, Thirman MJ, Wickrema A, van Besien K, Larson RA, Stock W. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7. PMID: 18297531.
      Citations: 2     Fields:    Translation:Humans
    299. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y, IRIS (International Randomized Interferon vs STI571) Study Group. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008 Apr 15; 111(8):4022-8. PMID: 18256322.
      Citations: 202     Fields:    Translation:HumansCTClinical Trials
    300. Odenike OM, Larson RA, Gajria D, Dolan ME, Delaney SM, Karrison TG, Ratain MJ, Stock W. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9. PMID: 18217206; PMCID: PMC4283497.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    301. Mi S, Lu J, Sun M, Li Z, Zhang H, Neilly MB, Wang Y, Qian Z, Jin J, Zhang Y, Bohlander SK, Le Beau MM, Larson RA, Golub TR, Rowley JD, Chen J. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):19971-6. PMID: 18056805; PMCID: PMC2148407.
      Citations: 199     Fields:    Translation:HumansCells
    302. Larson RA. Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine. Semin Oncol. 2007 Dec; 34(6 Suppl 5):S13-20. PMID: 18086342.
      Citations: 14     Fields:    Translation:Humans
    303. Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG, Kuliczkowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, Kwong YL, Baccarani M, Hughes T, Martinelli G, Radich JP, Zheng M, Shou Y, Kantarjian H, le Coutre P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008 Feb 15; 111(4):1834-9. PMID: 18048643.
      Citations: 85     Fields:    Translation:HumansCTClinical Trials
    304. Gupta G, Larson RA, Jampol LM. Chronic lymphocytic leukemia masquerading as uveitis. Retina. 2007 Nov-Dec; 27(9):1311-2. PMID: 18046244.
      Citations:    Fields:    Translation:Humans
    305. Whitman SP, Ruppert AS, Radmacher MD, Paschka P, Langer C, Baldus CD, Wen J, Racke F, Powell BL, Kolitz JE, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD, Mrózek K. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2008 Feb 01; 111(3):1552-9. PMID: 17940205; PMCID: PMC2214747.
      Citations: 105     Fields:    Translation:Humans
    306. Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM, Rich E, Smith SM, Zimmerman T, Zhang Y, Huo D, Larson R, van Besien K. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007 Dec; 40(11):1027-32. PMID: 17846595.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    307. Hill BT, Kondapalli L, Artz A, Smith S, Rich E, Godley L, Odenike O, Pursell KJ, Larson RA, Stock W, van Besien K. Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leuk Lymphoma. 2007 Sep; 48(9):1799-805. PMID: 17786717.
      Citations: 6     Fields:    Translation:Humans
    308. Marcucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P, Langer C, Baldus CD, Carroll AJ, Powell BL, Kolitz JE, Larson RA, Bloomfield CD, Cancer and Leukemia Group B Study, Mrózek K. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 2007 Aug 01; 25(22):3337-43. PMID: 17577018.
      Citations: 80     Fields:    Translation:HumansCells
    309. Martinelli G, Simonsson B, Guilhot F, Larson RA, Rege-Cambrin G, Radich J, Hochhaus A, Apanovitch AM, Gollerkeri A, Coutre S, Ottmann O, Dombret H. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007 Oct 01; 110(7):2309-15. PMID: 17496201.
      Citations: 127     Fields:    Translation:HumansCTClinical Trials
    310. Samara MA, Brennan JM, Van Besien K, Larson RA. Cardiac tamponade in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2007 Apr; 48(4):829-32. PMID: 17454648.
      Citations: 2     Fields:    Translation:Humans
    311. DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007 Jun 15; 109(12):5136-42. PMID: 17344466; PMCID: PMC1941786.
      Citations: 84     Fields:    Translation:HumansCTClinical Trials
    312. Whitman SP, Ruppert AS, Marcucci G, Paschka P, Langer C, Baldus CD, Wen J, Vukosavljevic T, Powell BL, Carroll AJ, Kolitz JE, Larson RA, Caligiuri MA, Bloomfield CD, Mrózek K. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood. 2007 Jun 15; 109(12):5164-7. PMID: 17341662; PMCID: PMC1890839.
      Citations: 41     Fields:    Translation:HumansCells
    313. Larson RA. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? Best Pract Res Clin Haematol. 2007 Mar; 20(1):29-37. PMID: 17336252.
      Citations: 30     Fields:    Translation:Humans
    314. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, Flinn IW, Tallman MS, Appelbaum FR, Larson RA, Paietta E, Jelinek DF, Gribben JG, Byrd JC. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol. 2007 Mar 01; 25(7):799-804. PMID: 17283363.
      Citations: 106     Fields:    Translation:HumansCellsCTClinical Trials
    315. Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF, Tallman MS. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007 Mar 01; 25(7):793-8. PMID: 17283364.
      Citations: 108     Fields:    Translation:HumansCTClinical Trials
    316. Singh ZN, Huo D, Anastasi J, Smith SM, Karrison T, Le Beau MM, Larson RA, Vardiman JW. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol. 2007 Feb; 127(2):197-205. PMID: 17210514.
      Citations: 37     Fields:    Translation:Humans
    317. Wetzler M, Sanford BL, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, Kolitz JE, Bloomfield CD, Larson RA. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007 May 15; 109(10):4164-7. PMID: 17264295; PMCID: PMC1885493.
      Citations: 54     Fields:    Translation:HumansCTClinical Trials
    318. Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, Amadori S, de Souza CA, Lipton JH, Hochhaus A, Heim D, Larson RA, Branford S, Muller MC, Agarwal P, Gollerkeri A, Talpaz M. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007 May 15; 109(10):4143-50. PMID: 17264298.
      Citations: 104     Fields:    Translation:HumansCTClinical Trials
    319. Larson RA. Etiology and management of therapy-related myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2007; 453-9. PMID: 18024664.
      Citations: 34     Fields:    Translation:Humans
    320. Druker BJ, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, IRIS Investigators, Guilhot F. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006 Dec 07; 355(23):2408-17. PMID: 17151364.
      Citations: 1236     Fields:    Translation:Humans
    321. Appelbaum FR, Rosenblum D, Arceci RJ, Carroll WL, Breitfeld PP, Forman SJ, Larson RA, Lee SJ, Murphy SB, O'Brien S, Radich J, Scher NS, Smith FO, Stone RM, Tallman MS. End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood. 2007 Mar 01; 109(5):1810-6. PMID: 17095617.
      Citations: 37     Fields:    Translation:Humans
    322. Kline J, Larson RA. Nelarabine in the treatment of refractory T-cell malignant diseases. Expert Opin Pharmacother. 2006 Sep; 7(13):1791-9. PMID: 16925505.
      Citations:    Fields:    Translation:HumansAnimals
    323. Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O, Zimmerman T, Smith S, Godley L, Thirman M, Daugherty C, Extermann M, Larson R, van Besien K. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 Sep; 12(9):954-64. PMID: 16920562.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    324. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA, Cancer and Leukemia Group B. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006 Aug 20; 24(24):3895-903. PMID: 16921040.
      Citations: 193     Fields:    Translation:Humans
    325. Paschka P, Marcucci G, Ruppert AS, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ, Kolitz JE, Larson RA, Bloomfield CD, Cancer and Leukemia Group B, Mrózek K. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006 Aug 20; 24(24):3904-11. PMID: 16921041.
      Citations: 205     Fields:    Translation:Humans
    326. Larson RA, Stone RM, Mayer RJ, Schiffer CA. Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3556s-63s. PMID: 16740785.
      Citations: 3     Fields:    Translation:Humans
    327. Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R, European LeukemiaNet, Baccarani M, Guilhot F. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006 Sep 15; 108(6):1809-20. PMID: 16709930.
      Citations: 321     Fields:    Translation:HumansCells
    328. Radmacher MD, Marcucci G, Ruppert AS, Whitman SP, Vardiman JW, Paschka P, Vukosavljevic T, Baldus CD, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD, Cancer and Leukemia Group B, Mrózek K. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood. 2006 Sep 01; 108(5):1677-83. PMID: 16670265; PMCID: PMC1895508.
      Citations: 48     Fields:    Translation:Humans
    329. Stock W, Yu D, Karrison T, Sher D, Stone RM, Larson RA, Bloomfield CD. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. Int J Oncol. 2006 May; 28(5):1099-103. PMID: 16596225.
      Citations: 9     Fields:    Translation:HumansCells
    330. Krahnke T, Druker BJ, Larson RA, O'Brien S, So C, Massimini G, Roy L, Guilhot J, Guerci-Bresler A, Guilhot F. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 2006 Sep 01; 108(5):1478-84. PMID: 16627756.
      Citations: 60     Fields:    Translation:Humans
    331. Slovak ML, Gundacker H, Bloomfield CD, Dewald G, Appelbaum FR, Larson RA, Tallman MS, Bennett JM, Stirewalt DL, Meshinchi S, Willman CL, Ravindranath Y, Alonzo TA, Carroll AJ, Raimondi SC, Heerema NA. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia. 2006 Jul; 20(7):1295-7. PMID: 16628187.
      Citations: 26     Fields:    Translation:HumansCells
    332. Larson RA. Management of acute lymphoblastic leukemia in older patients. Semin Hematol. 2006 Apr; 43(2):126-33. PMID: 16616046.
      Citations: 25     Fields:    Translation:Humans
    333. Cancer and Leukemia Group B 8461, Farag SS, Archer KJ, Ruppert AS, Carroll AJ, Vardiman JW, Pettenati MJ, Baer MR, Qumsiyeh MB, Koduru PR, Ning Y, Mayer RJ, Stone RM, Larson RA, Bloomfield CD, Mrózek K. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006 Jul 01; 108(1):63-73. PMID: 16522815; PMCID: PMC1895823.
      Citations: 110     Fields:    Translation:Humans
    334. Friedenberg WR, Rue M, Blood EA, Dalton WS, Shustik C, Larson RA, Sonneveld P, Greipp PR. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer. 2006 Feb 15; 106(4):830-8. PMID: 16419071.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    335. Kline J, Pollyea DA, Stock W, Artz A, Rich E, Godley L, Zimmerman T, Thompson K, Pursell K, Larson RA, van Besien K. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant. 2006 Feb; 37(3):307-10. PMID: 16400339.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    336. Lee S, Chen J, Zhou G, Shi RZ, Bouffard GG, Kocherginsky M, Ge X, Sun M, Jayathilaka N, Kim YC, Emmanuel N, Bohlander SK, Minden M, Kline J, Ozer O, Larson RA, LeBeau MM, Green ED, Trent J, Karrison T, Liu PP, Wang SM, Rowley JD. Gene expression profiles in acute myeloid leukemia with common translocations using SAGE. Proc Natl Acad Sci U S A. 2006 Jan 24; 103(4):1030-5. PMID: 16418266; PMCID: PMC1347995.
      Citations: 17     Fields:    Translation:HumansCells
    337. Larson RA. Myelodysplasia: when to treat and how. Best Pract Res Clin Haematol. 2006; 19(2):293-300. PMID: 16516126.
      Citations: 5     Fields:    Translation:HumansCells
    338. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P, Larson RA, Parsons S, Seidenfeld J, Weisdorf D, McCarthy PL. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant. 2006 Jan; 12(1):1-30. PMID: 16399566.
      Citations: 20     Fields:    Translation:Humans
    339. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, Lampson B, Larson RA, Caligiuri MA, Heerema NA. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006 Jan 20; 24(3):437-43. PMID: 16344317.
      Citations: 77     Fields:    Translation:HumansCells
    340. Kline JP, Larson RA. Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review. Expert Opin Pharmacother. 2005 Dec; 6(15):2711-8. PMID: 16316309.
      Citations: 3     Fields:    Translation:Humans
    341. Cole PD, Drachtman RA, Smith AK, Cate S, Larson RA, Hawkins DS, Holcenberg J, Kelly K, Kamen BA. Phase II trial of oral aminopterin for adults and children with refractory acute leukemia. Clin Cancer Res. 2005 Nov 15; 11(22):8089-96. PMID: 16299240; PMCID: PMC2906753.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    342. Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Whitman SP, Kolitz JE, Edwards CG, Vardiman JW, Powell BL, Baer MR, Moore JO, Perrotti D, Caligiuri MA, Carroll AJ, Larson RA, de la Chapelle A, Bloomfield CD, Mrózek K. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Dec 20; 23(36):9234-42. PMID: 16275934.
      Citations: 95     Fields:    Translation:HumansCells
    343. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P, Larson RA, Parsons S, Seidenfeld J, Weisdorf D, McCarthy PL. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transplant. 2005 Nov; 11(11):823-61. PMID: 16275588.
      Citations: 19     Fields:    Translation:Humans
    344. Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, Larson RA, Rai K, Petric R, Ramon-Suerez J, Gabrilove J, Grever MR. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res. 2005 Nov; 29(11):1253-7. PMID: 15916806.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    345. Larson RA, Sievers EL, Stadtmauer EA, Estey EH, Theobald M, Voliotis D, Bennett JM, Richie M, Leopold LH, Berger MS, Sherman ML, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR, Löwenberg B, Dombret H. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005 Oct 01; 104(7):1442-52. PMID: 16116598.
      Citations: 137     Fields:    Translation:Humans
    346. Klein CE, Kastrissios H, Miller AA, Hollis D, Yu D, Rosner GL, Grinblatt DL, Larson RA, Ratain MJ. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol. 2006 Jan; 57(2):199-206. PMID: 16158312.
      Citations: 5     Fields:    Translation:Humans
    347. Marcucci G, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD, Mrózek K. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Aug 20; 23(24):5705-17. PMID: 16110030.
      Citations: 142     Fields:    Translation:Humans
    348. van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L, Jones D, Del Cerro P, Bennett D, Casey B, Odenike O, Thirman M, Daugherty C, Wickrema A, Zimmerman T, Larson RA, Stock W. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38. PMID: 16009946.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    349. Byrd JC, Peterson BL, Gabrilove J, Odenike OM, Grever MR, Rai K, Larson RA, Cancer and Leukemia Group B. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res. 2005 Jun 01; 11(11):4176-81. PMID: 15930354.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    350. Neubauer A, Maharry K, Marcucci G, Mrózek K, Mayer RJ, Larson RA, Liu ET, Bloomfield CD. Patients (pts) with acute myeloid leukemia (AML) and mutant RAS benefit from high-dose cytarabine (HDAC) intensification: A Cancer and Leukemia Group B (CALGB) study. J Clin Oncol. 2005 Jun; 23(16_suppl):6514. PMID: 27943855.
      Citations:    
    351. Blum W, Mrózek K, Maharry K, Raimondi SC, Carroll AJ, Larson RA, Rowley JD, Bloomfield CD. Comparison of de novo vs. therapy-related acute leukemia (AL) and myelodysplastic syndromes (MDS) in adults with balanced chromosome aberrations of 11q23. J Clin Oncol. 2005 Jun; 23(16_suppl):6549. PMID: 27943878.
      Citations:    
    352. Baer MR, Shoemaker JS, Barrier R, Cuviello NW, O'Loughlin KL, Minderman H, Larson RA, Caligiuri MA. ATP-binding cassette (ABC) proteins in untreated acute myeloid leukemia (AML) in patients 60 years and older (CALGB 9760). J Clin Oncol. 2005 Jun; 23(16_suppl):6551. PMID: 27943894.
      Citations:    
    353. Kebriaei P, Kline J, Stock W, Kasza K, Le Beau MM, Larson RA, van Besien K. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant. 2005 May; 35(10):965-70. PMID: 15806131.
      Citations: 20     Fields:    Translation:Humans
    354. Larson RA, Le Beau MM. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans. Chem Biol Interact. 2005 May 30; 153-154:187-95. PMID: 15935816.
      Citations: 14     Fields:    Translation:HumansCells
    355. Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI, Blum W, Kefauver C, Sher DA, Green M, Moran M, Maharry K, Novick S, Bloomfield CD, Zwiebel JA, Larson RA, Grever MR, Chan KK, Byrd JC. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol. 2005 May 20; 23(15):3404-11. PMID: 15824414.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    356. Larson RA. Acute lymphoblastic leukemia: older patients and newer drugs. Hematology Am Soc Hematol Educ Program. 2005; 131-6. PMID: 16304370.
      Citations: 8     Fields:    Translation:HumansCells
    357. Zimmerman TM, Harlin H, Odenike OM, Berk S, Sprague E, Karrison T, Stock W, Larson RA, Ratain MJ, Gajewski TF. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22. PMID: 15570084.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    358. Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, Baer MR, Davey FR, Bloomfield CD, Larson RA, Schiffer CA. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood. 2005 May 01; 105(9):3420-7. PMID: 15572587; PMCID: PMC1895015.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    359. Farag SS, Ruppert AS, Mayer RJ, Stone RM, Carroll AJ, Powell BL, Moore JO, Pettenati MJ, Koduru PR, Stamberg J, Baer MR, Block AW, Vardiman JW, Kolitz JE, Schiffer CA, Larson RA, Bloomfield CD, Mrózek K. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol. 2005 Jan 20; 23(3):482-93. PMID: 15534356.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    360. Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, Velez-Garcia E, Moore JO, Shea TC, Hoke E, Caligiuri MA, Vardiman JW, Bloomfield CD, Larson RA, Cancer and Leukemia Group B. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol. 2004 Nov 01; 22(21):4290-301. PMID: 15514371.
      Citations: 69     Fields:    Translation:HumansCTClinical Trials
    361. Blum W, Ruppert AS, Carroll AJ, Rao KW, Pettenati MJ, Anastasi J, Larson RA, Bloomfield CD, Mrózek K. Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature. Cancer. 2004 Sep 15; 101(6):1420-7. PMID: 15368330.
      Citations: 14     Fields:    Translation:HumansCells
    362. Odenike OM, Sobecks RM, Janisch L, Huo D, Zimmerman TM, Daugherty CK, Ratain MJ, Larson RA. A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. Cancer Chemother Pharmacol. 2004 Dec; 54(6):553-61. PMID: 15349753.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    363. Dhodapkar MV, Hussein MA, Rasmussen E, Solomon A, Larson RA, Crowley JJ, Barlogie B, United States Intergroup Trial Southwest Oncology Group. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood. 2004 Dec 01; 104(12):3520-6. PMID: 15308571.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    364. Farag SS, Ruppert AS, Carroll AJ, Pettenati MJ, Le Beau MM, Peterson BL, Powell BL, Ozer H, Silver RT, Larson RA, Bloomfield CD, Cancer and Leukemia Group B study, Mrózek K. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study. Int J Oncol. 2004 Jul; 25(1):143-51. PMID: 15201999.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    365. Marcucci G, Ruppert AS, Archer KJ, Pettenati MJ, Heerema NA, Carroll AJ, Koduru PR, Kolitz JE, Sterling LJ, Edwards CG, Anastasi J, Larson RA, Bloomfield CD, Mrózek K. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. J Clin Oncol. 2004 Jun 15; 22(12):2410-8. PMID: 15197203.
      Citations: 35     Fields:    Translation:Humans
    366. Van Besien K, Smith S, Anastasi J, Larson R, Thirman M, Odenike T, Stock W. Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. Blood. 2004 Jun 01; 103(11):4373-4. PMID: 15155474.
      Citations: 2     Fields:    Translation:HumansCells
    367. Larson RA. Adult ALL: where are we and where are we going? Clin Adv Hematol Oncol. 2004 Jun; 2(6):342-4. PMID: 16163203.
      Citations:    Fields:    Translation:Humans
    368. Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, Shepherd L, Hines JD, Schiffer CA, Larson RA. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005 Jan 01; 105(1):49-53. PMID: 15138165.
      Citations: 97     Fields:    Translation:Humans
    369. Kebriaei P, Winter JN, Laport GG, Le Beau MM, Dewald G, Larson RA. Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantation. Leuk Res. 2004 May; 28(5):537-40. PMID: 15068908.
      Citations:    Fields:    Translation:HumansCells
    370. Rizzieri DA, Johnson JL, Niedzwiecki D, Lee EJ, Vardiman JW, Powell BL, Barcos M, Bloomfield CD, Schiffer CA, Peterson BA, Canellos GP, Larson RA. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004 Apr 01; 100(7):1438-48. PMID: 15042678.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    371. Byrd JC, Ruppert AS, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Stamberg J, Koduru PR, Moore JO, Mayer RJ, Davey FR, Larson RA, Bloomfield CD, Mrózek K. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004 Mar 15; 22(6):1087-94. PMID: 15020610.
      Citations: 50     Fields:    Translation:HumansCellsCTClinical Trials
    372. Side LE, Curtiss NP, Teel K, Kratz C, Wang PW, Larson RA, Le Beau MM, Shannon KM. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes Chromosomes Cancer. 2004 Mar; 39(3):217-23. PMID: 14732923.
      Citations: 19     Fields:    Translation:HumansCells
    373. Sekeres MA, Peterson B, Dodge RK, Mayer RJ, Moore JO, Lee EJ, Kolitz J, Baer MR, Schiffer CA, Carroll AJ, Vardiman JW, Davey FR, Bloomfield CD, Larson RA, Stone RM, Cancer and Leukemia Group B. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 2004 Jun 01; 103(11):4036-42. PMID: 14976037.
      Citations: 39     Fields:    Translation:Humans
    374. Ferrando AA, Neuberg DS, Dodge RK, Paietta E, Larson RA, Wiernik PH, Rowe JM, Caligiuri MA, Bloomfield CD, Look AT. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet. 2004 Feb 14; 363(9408):535-6. PMID: 14975618.
      Citations: 40     Fields:    Translation:Humans
    375. Wetzler M, Dodge RK, Stewart CC, Carroll AJ, Tantravahi R, Vardiman JW, Larson RA, Bloomfield CD, Mrózek K. Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. Br J Haematol. 2004 Feb; 124(3):275-88. PMID: 14717774.
      Citations: 24     Fields:    Translation:HumansCells
    376. Bloomfield CD, Ruppert AS, Kolitz JE, Moore JO, Mayer RJ, Edwards CG, Sterling LJ, Vardiman JW, Carroll AJ, Pettenati MJ, Stamberg J, Byrd JC, Marcucci G, Larson RA, Cancer and Leukemia Group B (CALGB) Study 8461, Mrózek K. Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. Ann Hematol. 2004; 83 Suppl 1:S84-5. PMID: 15124687.
      Citations: 5     Fields:    Translation:HumansCells
    377. Marcucci G, Stock W, Dai G, Klisovic MI, Maharry K, Shen T, Liu S, Sher DA, Lucas D, Zwiebel A, Larson RA, Caligiuri MA, Bloomfield CD, Chan KK, Grever MR, Byrd JC. G3139, a BCL-2 antisense oligo-nucleotide, in AML. Ann Hematol. 2004; 83 Suppl 1:S93-4. PMID: 15124691.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    378. Larson RA. The U.S. trials in adult acute lymphoblastic leukemia. Ann Hematol. 2004; 83 Suppl 1:S127-8. PMID: 15124704.
      Citations: 7     Fields:    Translation:Humans
    379. Kolitz JE, George SL, Baer MR, Lee EJ, Bloomfield CD, Larson RA, Cancer and Leukemia Group B (CALGB) trials in younger and older adults. P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults. Ann Hematol. 2004; 83 Suppl 1:S103-4. PMID: 15124695.
      Citations: 1     Fields:    Translation:Humans
    380. Cheson BD, Bennett JM, Kopecky KJ, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Sanz MA, Head DR, Ohno R, Bloomfield CD, LoCocco F, International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes,, Büchner T, Löwenberg B. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003 Dec 15; 21(24):4642-9. PMID: 14673054.
      Citations: 1120     Fields:    Translation:Humans
    381. Larson RA, Daley GQ, Schiffer CA, Porcu P, Pui CH, Marie JP, Steelman LS, Bertrand FE, McCubrey JA. Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002. Leukemia. 2003 Dec; 17(12):2358-82. PMID: 14562120.
      Citations:    Fields:    Translation:Humans
    382. Giles FJ, Feldman EJ, Roboz GJ, Larson RA, Mamus SW, Cortes JE, Verstovsek S, Faderl S, Talpaz M, Beran M, Albitar M, O'Brien SM, Kantarjian HM. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leuk Res. 2003 Dec; 27(12):1091-6. PMID: 12921945.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    383. Kebriaei P, Larson RA. Progress and challenges in the therapy of adult acute lymphoblastic leukemia. Curr Opin Hematol. 2003 Jul; 10(4):284-9. PMID: 12799534.
      Citations: 3     Fields:    Translation:Humans
    384. Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Dobrez DG, Hensley ML, Cella D, IRIS Investigators. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol. 2003 Jun 01; 21(11):2138-46. PMID: 12775739.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    385. Baldus CD, Tanner SM, Ruppert AS, Whitman SP, Archer KJ, Marcucci G, Caligiuri MA, Carroll AJ, Vardiman JW, Powell BL, Allen SL, Moore JO, Larson RA, Kolitz JE, de la Chapelle A, Bloomfield CD. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood. 2003 Sep 01; 102(5):1613-8. PMID: 12750167.
      Citations: 71     Fields:    Translation:HumansCTClinical Trials
    386. Schiffer CA, Hehlmann R, Larson R. Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1). Leukemia. 2003 Apr; 17(4):691-9. PMID: 12682626.
      Citations: 8     Fields:    Translation:Humans
    387. Echlin-Bell DR, Smith LL, Li L, Strissel PL, Strick R, Gupta V, Banerjee J, Larson R, Relling MV, Raimondi SC, Hayashi Y, Taki T, Zeleznik-Le N, Rowley JD. Polymorphisms in the MLL breakpoint cluster region (BCR). Hum Genet. 2003 Jul; 113(1):80-91. PMID: 12665971.
      Citations: 5     Fields:    Translation:HumansCells
    388. Szatrowski TP, Dodge RK, Reynolds C, Westbrook CA, Frankel SR, Sklar J, Stewart CC, Hurd DD, Kolitz JE, Velez-Garcia E, Stone RM, Bloomfield CD, Schiffer CA, Larson RA. Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. Cancer. 2003 Mar 15; 97(6):1471-80. PMID: 12627512.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    389. Lensch MW, Tischkowitz M, Christianson TA, Reifsteck CA, Speckhart SA, Jakobs PM, O'Dwyer ME, Olson SB, Le Beau MM, Hodgson SV, Mathew CG, Larson RA, Bagby GC. Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia. Blood. 2003 Jul 01; 102(1):7-16. PMID: 12637330.
      Citations: 13     Fields:    Translation:HumansCells
    390. O'Brien SG, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, IRIS Investigators, Guilhot F. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003 Mar 13; 348(11):994-1004. PMID: 12637609.
      Citations: 945     Fields:    Translation:HumansCTClinical Trials
    391. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD, Larson RA. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003 Jul 01; 102(1):43-52. PMID: 12623843.
      Citations: 198     Fields:    Translation:Humans
    392. Navolanic PM, Pui CH, Larson RA, Bishop MR, Pearce TE, Cairo MS, Goldman SC, Jeha SC, Shanholtz CB, Leonard JP, McCubrey JA. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia. 2003 Mar; 17(3):499-514. PMID: 12646938.
      Citations: 16     Fields:    Translation:Humans
    393. Larson RA. Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia? Leukemia. 2003 Mar; 17(3):488-91. PMID: 12646935.
      Citations: 2     Fields:    Translation:Humans
    394. Byrd JC, Peterson B, Piro L, Saven A, Vardiman JW, Larson RA, Schiffer C. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia. 2003 Feb; 17(2):323-7. PMID: 12592330.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    395. Silver RT, Peterson BL, Szatrowski TP, Powell BL, Stock W, Carroll AJ, Bloomfield CD, Schiffer CA, Larson RA. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013. Leuk Lymphoma. 2003 Jan; 44(1):39-48. PMID: 12691141.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    396. Kebriaei P, Anastasi J, Larson RA. Acute lymphoblastic leukaemia: diagnosis and classification. Best Pract Res Clin Haematol. 2002 Dec; 15(4):597-621. PMID: 12617866.
      Citations: 13     Fields:    Translation:Humans
    397. Qian Z, Fernald AA, Godley LA, Larson RA, Le Beau MM, Qian Z, Fernald AA, Godley LA, Larson RA, Le Beau MM. Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci U S A. 2002 Nov 12; 99(23):14925-30. PMID: 12417757; PMCID: PMC137521.
      Citations: 45     Fields:    Translation:HumansCells
    398. Farag SS, Archer KJ, Vardiman JW, Carroll AJ, Pettenati MJ, Moore JO, Kolitz JE, Mayer RJ, Stone RM, Larson RA, Bloomfield CD, Farag SS, Archer KJ, Vardiman JW, Carroll AJ, Pettenati MJ, Moore JO, Kolitz JE, Mayer RJ, Stone RM, Larson RA, Bloomfield CD. Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Int J Oncol. 2002 Nov; 21(5):1041-51. PMID: 12370753.
      Citations: 11     Fields:    Translation:HumansCells
    399. Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shepherd L, Larson RA, Schiffer CA. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol. 2002 Sep 15; 20(18):3878-84. PMID: 12228208.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    400. Farag SS, George SL, Lee EJ, Baer M, Dodge RK, Becknell B, Fehniger TA, Silverman LR, Crawford J, Bloomfield CD, Larson RA, Schiffer CA, Caligiuri MA. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clin Cancer Res. 2002 Sep; 8(9):2812-9. PMID: 12231521.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    401. Larson RA, Boogaerts M, Estey E, Karanes C, Stadtmauer EA, Sievers EL, Mineur P, Bennett JM, Berger MS, Eten CB, Munteanu M, Loken MR, Van Dongen JJ, Bernstein ID, Appelbaum FR, Larson RA, Boogaerts M, Estey E, Karanes C, Stadtmauer EA, Sievers EL, Mineur P, Bennett JM, Berger MS, Eten CB, Munteanu M, Loken MR, Van Dongen JJ, Bernstein ID, Appelbaum FR, Mylotarg Study Group. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002 Sep; 16(9):1627-36. PMID: 12200674.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    402. Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA, Anastasi J, Powell BL, Kolitz JE, Schiffer CA, Bloomfield CD, Larson RA. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002 Aug 15; 100(4):1224-32. PMID: 12149202.
      Citations: 79     Fields:    Translation:HumansCTClinical Trials
    403. Byrd JC, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD, Cancer and Leukemia Group B (CALGB 8461), Mrózek K. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002 Dec 15; 100(13):4325-36. PMID: 12393746.
      Citations: 522     Fields:    Translation:HumansCellsCTClinical Trials
    404. Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, Vardiman JW, Rai K, Schiffer CA, Larson RA, Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, Vardiman JW, Rai K, Schiffer CA, Larson RA. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003 Jan 01; 101(1):6-14. PMID: 12393429.
      Citations: 115     Fields:    Translation:HumansCTClinical Trials
    405. Sato Y, Izumi T, Kanamori H, Davis EM, Miura Y, Larson RA, Le Beau MM, Ozawa K, Rowley JD. t(1;3)(p36;p21) is a recurring therapy-related translocation. Genes Chromosomes Cancer. 2002 Jun; 34(2):186-92. PMID: 11979552.
      Citations: 1     Fields:    Translation:HumansCells
    406. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002 May 15; 99(10):3530-9. PMID: 11986204.
      Citations: 243     Fields:    Translation:HumansCTClinical Trials
    407. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002 May 15; 20(10):2429-40. PMID: 12011120.
      Citations: 546     Fields:    Translation:HumansCTClinical Trials
    408. Kornblith AB, Herndon JE, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA, Holland JC. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002 May 15; 20(10):2441-52. PMID: 12011121.
      Citations: 91     Fields:    Translation:HumansCTClinical Trials
    409. Martell RE, Peterson BL, Cohen HJ, Petros WP, Rai KR, Morrison VA, Elias L, Shepherd L, Hines J, Larson RA, Schiffer CA, Hurwitz HI. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemother Pharmacol. 2002 Jul; 50(1):37-45. PMID: 12111110.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    410. Andersen MK, Larson RA, Mauritzson N, Schnittger S, Jhanwar SC, Pedersen-Bjergaard J. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer. 2002 Apr; 33(4):395-400. PMID: 11921273.
      Citations: 32     Fields:    Translation:HumansCells
    411. Zhang Y, Strissel P, Strick R, Chen J, Nucifora G, Le Beau MM, Larson RA, Rowley JD. Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia. Proc Natl Acad Sci U S A. 2002 Mar 05; 99(5):3070-5. PMID: 11867721; PMCID: PMC122474.
      Citations: 29     Fields:    Translation:HumansCells
    412. Diehl CA, Jafvert CT, Marley KA, Larson RA, Diehl CA, Jafvert CT, Marley KA, Larson RA. Surfactant-assisted UV-photolysis of nitroarenes. Chemosphere. 2002 Jan; 46(4):553-60. PMID: 11838434.
      Citations: 1     Fields:    
    413. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, Carroll AJ, Vardiman JW, George SL, Kolitz JE, Larson RA, Bloomfield CD, Caligiuri MA, Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, Carroll AJ, Vardiman JW, George SL, Kolitz JE, Larson RA, Bloomfield CD, Caligiuri MA. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001 Oct 01; 61(19):7233-9. PMID: 11585760.
      Citations: 202     Fields:    Translation:HumansCells
    414. Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shepherd L, Martell RE, Larson RA, Schiffer CA, Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shepherd L, Martell RE, Larson RA, Schiffer CA. Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol. 2001 Aug 15; 19(16):3611-21. PMID: 11504743.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    415. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR, Mylotarg Study Group, Löwenberg B. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001 Jul 01; 19(13):3244-54. PMID: 11432892.
      Citations: 206     Fields:    Translation:HumansCTClinical Trials
    416. Larson RA, Larson RA. Current use and future development of gemtuzumab ozogamicin. Semin Hematol. 2001 Jul; 38(3 Suppl 6):24-31. PMID: 11474494.
      Citations: 4     Fields:    Translation:Humans
    417. Baer MR, Stewart CC, Dodge RK, Leget G, Schiffer CA, Powell BL, Kolitz JE, Moore JO, Stone RM, Davey FR, Carroll AJ, Larson RA, Bloomfield CD, Sulé N, Mrózek K. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood. 2001 Jun 01; 97(11):3574-80. PMID: 11369653.
      Citations: 46     Fields:    Translation:Humans
    418. Siston AK, List MA, Daugherty CK, Banik DM, Menke C, Cornetta K, Larson RA. Psychosocial adjustment of patients and caregivers prior to allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001 Jun; 27(11):1181-8. PMID: 11551029.
      Citations: 19     Fields:    Translation:Humans
    419. Prior TW, Edwards C, Marcucci G, Carroll AJ, Snyder PJ, Koduru PR, Theil KS, Pettenati MJ, Archer KJ, Caligiuri MA, Vardiman JW, Kolitz JE, Larson RA, Bloomfield CD, Mrózek K. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 2001 May 01; 19(9):2482-92. PMID: 11331327.
      Citations: 21     Fields:    Translation:HumansCells
    420. Larson RA. New agents for induction and postremission therapy of acute myeloid leukemia. Leukemia. 2001 Apr; 15(4):675-6. PMID: 11368378.
      Citations: 1     Fields:    Translation:Humans
    421. Cataland SR, Daugherty CK, Weseman EC, Larson RA, Cataland SR, Daugherty CK, Weseman EC, Larson RA. Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2001 Apr; 41(3-4):297-307. PMID: 11378542.
      Citations: 3     Fields:    Translation:Humans
    422. Cervini-Silva J, Larson RA, Wu J, Stucki JW. Transformation of chlorinated aliphatic compounds by ferruginous smectite. Environ Sci Technol. 2001 Feb 15; 35(4):805-9. PMID: 11349296.
      Citations: 1     Fields:    Translation:Cells
    423. Lai F, Godley LA, Joslin J, Fernald AA, Liu J, Espinosa R, Zhao N, Pamintuan L, Till BG, Larson RA, Qian Z, Le Beau MM. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics. 2001 Jan 15; 71(2):235-45. PMID: 11161817.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    424. Larson R. Children and adolescents in a changing media world. Monogr Soc Res Child Dev. 2001; 66(1):148-54. PMID: 11326590.
      Citations:    Fields:    Translation:Humans
    425. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000 Dec 14; 343(24):1750-7. PMID: 11114313.
      Citations: 205     Fields:    Translation:HumansCTClinical Trials
    426. Larson RA. Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol Oncol Clin North Am. 2000 Dec; 14(6):1367-79, x. PMID: 11147228.
      Citations: 7     Fields:    Translation:HumansCells
    427. Larson RA. Myeloid leukemia after cytotoxic therapy and other hematotoxins. J Toxicol Environ Health A. 2000 Nov; 61(5-6):381-6. PMID: 11086943.
      Citations: 1     Fields:    Translation:Humans
    428. Preisler HD, Venugopal P, Gregory SA, Hsu W, Loew J, Adler S, Gezer S, Creech S, Galvez A, Slivnick D, Andric T, Larson RA, Jajeh A. Poor prognosis acute myelogenous leukemia: 1 - response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine). Leuk Res. 2000 Aug; 24(8):671-80. PMID: 10936421.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    429. Wang PW, Eisenbart JD, Espinosa R, Davis EM, Larson RA, Le Beau MM. Refinement of the smallest commonly deleted segment of chromosome 20 in malignant myeloid diseases and development of a PAC-based physical and transcription map. Genomics. 2000 Jul 01; 67(1):28-39. PMID: 10945467.
      Citations: 5     Fields:    Translation:HumansCells
    430. Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, Zani VJ, Stone RM. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000 Apr 15; 95(8):2530-5. PMID: 10753831.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    431. Sobecks RM, Daugherty CK, Hallahan DE, Laport GF, Wagner ND, Larson RA. A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies. Bone Marrow Transplant. 2000 Apr; 25(8):807-13. PMID: 10808200.
      Citations: 10     Fields:    Translation:HumansCells
    432. Hensley ML, Peterson B, Silver RT, Larson RA, Schiffer CA, Szatrowski TP. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. J Clin Oncol. 2000 Mar; 18(6):1301-8. PMID: 10715301.
      Citations: 6     Fields:    Translation:Humans
    433. Larson RA, Wang Y, Banerjee M, Wiemels J, Hartford C, Le Beau MM, Smith MT. Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood. 1999 Jul 15; 94(2):803-7. PMID: 10397748.
      Citations: 56     Fields:    Translation:HumansCells
    434. Czuczman MS, Dodge RK, Stewart CC, Frankel SR, Davey FR, Powell BL, Szatrowski TP, Schiffer CA, Larson RA, Bloomfield CD. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood. 1999 Jun 01; 93(11):3931-9. PMID: 10339502.
      Citations: 14     Fields:    Translation:HumansCells
    435. Wetzler M, Dodge RK, Carroll AJ, Tantravahi R, Block AW, Pettenati MJ, Le Beau MM, Frankel SR, Stewart CC, Szatrowski TP, Schiffer CA, Larson RA, Bloomfield CD, Mrózek K. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood. 1999 Jun 01; 93(11):3983-93. PMID: 10339508.
      Citations: 61     Fields:    Translation:Humans
    436. Toljanic JA, Bedard JF, Larson RA, Fox JP. A prospective pilot study to evaluate a new dental assessment and treatment paradigm for patients scheduled to undergo intensive chemotherapy for cancer. Cancer. 1999 Apr 15; 85(8):1843-8. PMID: 10223580.
      Citations: 18     Fields:    Translation:Humans
    437. Finiewicz KJ, Larson RA. Dose-intensive therapy for adult acute lymphoblastic leukemia. Semin Oncol. 1999 Feb; 26(1):6-20. PMID: 10073558.
      Citations:    Fields:    Translation:Humans
    438. Roulston D, Espinosa R, Nucifora G, Larson RA, Le Beau MM, Rowley JD. CBFA2(AML1) translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy. Blood. 1998 Oct 15; 92(8):2879-85. PMID: 9763573.
      Citations: 15     Fields:    Translation:HumansCells
    439. Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ, Schulman P, Davey FR, Frankel SR, Bloomfield CD, George SL, Schiffer CA. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998 Sep 01; 92(5):1556-64. PMID: 9716583.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    440. Allen RJ, Smith SD, Moldwin RL, Lu MM, Giordano L, Vignon C, Suto Y, Harden A, Tomek R, Veldman T, Ried T, Larson RA, Le Beau MM, Rowley JD, Zeleznik-Le N. Establishment and characterization of a megakaryoblast cell line with amplification of MLL. Leukemia. 1998 Jul; 12(7):1119-27. PMID: 9665199.
      Citations: 7     Fields:    Translation:HumansCells
    441. Larson RA, Fretzin MH, Dodge RK, Schiffer CA. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia. 1998 May; 12(5):660-5. PMID: 9593262.
      Citations: 11     Fields: